Exam 1 Flashcards

1
Q

Division of PNS

  • 2 divisions
  • 2 systems
A
  • •Efferent Division
    • •Autonomic system
      • •Parasympathetic
      • •Sympathetic
      • •Enteric
    • •Somatic system (no ganglion)
  • •Afferent division:
    • • Afferent nerves provide sensory input to the CNS that in turn modulates the efferent division (reflex arcs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

General anatomy (explain)

A
  • •Parasympathetic and sympathetic ANS
    • •CNS → Preganglionic nerve → Ganglia → Postganglionic nerve → Effectors
  • •Sympathetic ANS
    • •CNS → preganglionic nerve → adrenal → Epinephrine (80%) & norepinephrine (20%)
  • •CNS → Efferent somatic nerve → Neuromuscular Junction at skeletal muscle → skeletal muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe autonomic outflow from CNS (both parasympathetic and sympathetic)

A

•Parasympathetic

  • oPreganglionic nerves emerge from the brain stem and from the sacral region of the spinal cord (Craniosacral)
  • oCranial outflow via cranial nerves III (oculomotor), VII (facial), IX (glossopharyngeal) and X (vagus)

•Sympathetic

  • oPreganglionic neurons of the sympathetic nerves system emerge from the thoracic and lumbar regions (T1 to L2) of the spinal cord
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Identify functions of the PNS (7)

**Is it essential for life?

A
  • •Preganglionic nerves are long and postganglionic nerves are short
  • •Ganglia are near or within effector organ
  • •One-to-one connection between pre and postganglionic nerves, allowing for discrete, fine control of effector targets.
  • •Essential for life
  • •Visceral emptying
  • •Conservation, and replenishment of body resources
  • •Effects are usually (but not always) antagonistic towards sympathetic effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Identify features of SNS (6)

**Is it essential for life?

A
  • •Preganglionic nerves are short and postganglionic nerves are long
  • •Extensive preganglionic branching (affecting several ganglia), postganglionic nerves are branched at effector targets. Thus, a single stimulus can initiate a large response.
  • •Diffuse and extensive innervation throughout body
  • •Not essential for life
  • •Adaptation to stress
  • •Induces fight or flight response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  • Be able to diagram the steps in the synthesis, storage, release, receptor interaction and termination of the action of acetylcholine (ACh) released from cholinergic neurons.

***WHat is the neurotransmitter of cholinergic nerves vs adrenergic nerves?

A
  • ·Acetylcholine (ACh) is the neurotransmitter of cholinergic nerves
  • ·Norepinephrine (NE) is the neurotransmitter of adrenergic nerves
  • First ANS nerve “out” of the CNS is a cholinergic nerve.
  • ACh is the neurotransmitter at all autonomic ganglia
  • •ACh induces the Adrenal to release Epinephrine (Epi)
  • •ACh is the neurotransmitter at the neuromuscular junction
  • •Most postganglionic parasympathetic nerves are cholinergic (those that are not release nitric oxide)
  • -Postganglionic sympathetic nerves that innervate sweat glands are cholinergic
  • -The remaining postganglionic sympathetic nerves are adrenergic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Steps in cholinergic neurotransmission

A
  • oActive uptake of choline into the nerve ending
  • oAddition of acetyl group to choline by choline acetyl transferase (CAT) to form ACh
  • oUptake and storage of ACh in vesicles
  • oCa2+-dependent exocytosis release of ACh in response to action potential
  • oReversible interaction of ACh with presynaptic and postsynaptic nicotinic and muscarinic receptors.
  • oPresynaptic muscarinic receptors suppress the release of ACh (negative feedback control) from the cholinergic nerve
  • oPostsynaptic muscarinic receptors are located at effector target tissue
  • oPostsynaptic nicotinic receptors are located in ganglia and at the neuromuscular junction
  • oRapid hydrolysis of ACh by acetylcholinesterase (AChE) to form choline and acetate
  • oCholine actively taken up by cholinergic nerve (back to the first bullet point)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

•To know which drugs affect cholinergic transmission

  1. Blocks Na channels which in turn prevents action potentials
  2. Blocks the uptake of choline which in turn prevents ACh synthesis
  3. Induces transient release of ACh, and a subsequent permanent block. It, therefore, has transient cholinomimetic effects followed by anticholinergic effects.
  4. Prevents the release of ACh. It, therefore, has anticholinergic effects.
  5. Agonist of the muscarinic receptor. It, therefore, has cholinomimetic effects.
  6. oAgonist of nicotinic receptors. Induces transient activation of nicotinic receptors, and a subsequent block. It, therefore, initially has cholinomimetic effects followed by anticholinergic effects.
A
  1. Tetrodotoxin and saxitoxin
  2. ·Hemichlolinum
  3. ·Black Widow Spider; more specific to cholinergic nerves. Initiate transient release of Ach from cholinergic nerves.
  4. Botulinus toxin; act as muscle relaxant, prevent migraine attacks. Specific to Ach
  5. Bethanechol
  6. Nicotine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drugs that affect cholinergic neurotransmission

  1. Antagonist of muscarinic receptors. It, therefore, has anticholinergic effects.
  2. oAntagonist of ganglionic nicotinic receptors. It, therefore, has anticholinergic effects.
  3. oAntagonist of the neuromuscular junction nicotinic receptors. It, therefore, induces skeletal muscle paralysis.
  4. Anticholinesterase that by inhibiting acetylcholinesterase (AChE) increases ACh at all cholinergic synapses. It, therefore, has initial cholinomimetic effects followed by anticholinergic effects.
A
  1. Atropine
  2. Mecamylamine; only block with nicotinic receptors at the ganglia
  3. Curare (used in surgery)
  4. Physotigmine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

•To introduce the physiological effects of Muscarinic Receptors

  • Cholinergic effects at skeletal muscle
  • Cholinergic effects at muscarinic receptors
A

•Skeletal Muscle

  • •ACh stimulates nicotinic receptors at the neuromuscular junction (NMJ)
  • •Nicotinic receptor is a ligand-gated cation channel. Its activation induces the influx of Na+ ions and depolarization
  • •Depolarization causes a muscle action potential and leads to contraction

•Muscarinic receptors

  • oACh stimulates muscarinic receptors at various effector target tissue.
  • oMuscarinic Receptors are G protein coupled receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  • Cholinergic effects at autonomic ganglia
  • Cholinergic effects at
A

•Autonomic Ganglia

  • •ACh stimulates nicotinic receptors at Ganglia.
  • •Nicotinic receptors at Ganglia resemble nicotinic receptors at the neuromuscular junction (NMJ) because they are ligand-gated cation channels that upon activation induce depolarization.
  • •However, nicotinic receptors at Ganglia are not identical to those at NMJ

•Presynaptic Receptors

  • •ACh binding to Muscarinic receptors (M) located on the presynaptic cholinergic neuron inhibits ACh release.
  • •M2 and M4 are presynaptic receptors that suppress ACh release.
  • •Norepinephrine (NE) binding to presynaptic α2 receptors inhibits the release of NE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Physiolgic effects of muscarinic receptors

  • 5 subtypes and functions
  • do drugs target all 5 subtypes?
  • which types are stimulatory (induce calcium based signaling to modulate effector targets)
  • which types are inhibitory
  • what slows the heart down? (major muscarinic receptor in the heart)
  • major rle in CNS?
  • majo role in visceral ?
A
  • •Five distinct subtypes of muscarinic receptors (M) (M1-M5)
  • •The muscarinic drugs are non-specific, meaning that each muscarinic receptor-targeting drug will bind to all five muscarinic receptor subtypes.
  • •In general, M1, M3, and M5 (thus the odd numbers) are stimulatory and they induce Calcium –based signaling to modulate effector targets.
  • •In general, M2, and M4 (thus the even numbers) are inhibitory. Meaning they induce inhibitory signaling at effector targets by inducing hyperpolarization and decreasing cAMP signaling
  • •M2 is the major muscarinic receptor in the heart. It slows down heart rate (SA node), conduction (AV node) and contraction (atria > ventricle)
  • •M1 plays a major role in the CNS (brain).
  • •M3 plays a major role at visceral targets and is stimulatory inducing smooth muscle contraction (GI, bladder, pulmonary), secretion from glands and the eye.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

•Be able to outline the processes involved in the synthesis, storage, release, receptor interaction and termination of action of NE (norepinephrine) and Epi (epinephrine) released from adrenergic nerve endings and the adrenal medulla.

A

Storage of NE

  • •Vesicular amine transporter (VAT) mediates the uptake of dopamine and NE into intracellular storage vesicles
  • •Being in a vesicle protects NE from being degraded
  • •Dopamine is converted to NE in vesicles (by DβH)
  • •Reserpine blocks NE and dopamine uptake by vesicles

Release of NE

  • Depolarization → Ca2+ enters the neuron → triggers the fusion of the vesicle with the plasma membrane → exocytosis release of NE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Identify NE and Epi interaction with adrenergic receptors

A
  • NE interacts with α1, α2, β1
  • Epi interactions with α1, α2, β1, β2
  • Note at β2 receptors Epi >>> NE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe ways of terminating the action of NE

  • Active reuptake
  • Metabolism
  • MAO
  • COMT
A

Active Reuptake of NE into nerve terminal

  • •most important in terminating action of neuron-released NE
  • •NE transporter (NET) mediates the active uptake of NE

Metabolism

  • •Less important than reuptake in terminating action of neuron-released NE

Monoamine Oxidase (MAO)

  • •non-specific - metabolizes many monoamines
  • •in nerve terminals → metabolism of amines in cytoplasmic pool
  • •in liver, kidney & gut (also in other tissues)
  • •protects against circulating and exogenous biologically active amines

Catechol-O-methyl-transferase (COMT)

  • •specifically metabolizes catechols (NE, Epi, Dopamine)
  • •widely distributed (e.g. liver, kidney, brain)
  • •important for metabolism of circulating catecholamines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Metabolites of NE and Epi

**DO you find NE and Epi in urine? what do you find? (3)

A
  • •both MAO & COMT usually act on Epi & NE before excretion
  • •most abundant urinary metabolite is 3-Methoxy-4-hydroxy-mandelic acid (VMA)
  • •other metabolites include: metanephrine and normetanephrine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Effects of drugs on adrenergic neurotransmission. **Identify the drugs

  1. Inhibit tyrosine hydroxylase
    • ​​Used to reduce NE & Epi in pheochromocytoma
  2. Displacement of Transmitter from Nerve Terminal
    • enter the nerve terminal via amine uptake pump (NET) causing a rapid release of NE → sympathomimetic effect
  3. •induces release of NE → sympathomimetic effect
  • no direct effect at receptors
  • Dietary constituent

effects enhanced by MAOIs → hypertensive crisis

A
  1. Metyrosine
  2. Many Amines e.g Tyramine (releasing agents)
  3. Tyramine
    • Can induce hypertensive crisis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Identify drug and adverse effects

  • •Effects
    • •Promotes the release of NE → sympathomimetic effect
    • •peripheral effects similar to NE (vasoconstriction → ↑ TPR (total peripheral resistance), ↑ HR)
    • •+ pronounced CNS stimulation
  • •Clinical uses
    • •attention deficit/hyperactivity disorder (ADHD)
    • •narcolepsy
    • •Obesity (short term)
A

Amphetamine (Adderall)

Adverse effects

  • •similar to NE
  • •+ marked CNS effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Identify drug

  • •α1, α2, β1, β2 agonist and it also stimulates the release of NE and Epi
  • •Clinical uses
    • •Hypotension in the setting of anesthesia
  • •Effects similar to Amphetamine
A

Ephedrine

  • Not everyday use. can cause hypertension. so only use when you are hypotensive from anesthesia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Identify drug that Block reuptake into nerve terminal

  • •inhibition of NE reuptake → ↑NE in synapse → ↑NE effects sympathomimetic
A

•Cocaine and Imipramine (Antidepressant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

identify drug that inhibit MAO (MAOIs) - 3

•Effects:

  • •Potentiates monoamine neurotransmitter activity in the CNS

•Clinical use:

  • •Major depressive order
A

•Tranylcypromine, Phenelzine and Selegiline

  • •predispose patients toward hypertensive crises
  • •MAO in liver & gut protects against exogenous active amines (e.g. tyramine)
  • •MAO inhibition → ↑ circulating levels of dietary amines → hypertension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Effects mediated by adrenergic receptor

  1. •α1-Receptor mediated effects (4)
  2. •β1-Receptor mediated effects (3)
A

1. α1-Receptor mediated effects

  • mydriasis (contraction of the iris dilator muscle in eye)
  • constriction of arteries & veins
  • constriction of GI & GU sphincters
  • ejaculation, orgasm (β receptors also involved)

2. β1-Receptor mediated effects

  • •Heart
    • o↑ automaticity (SA) → ↑ HR
    • o↑ contractility (atria and ventricles)
    • o↑ conduction velocity (AV node)
  • •↑ renin secretion → ↑ plasma renin activity
  • •↑ lipolysis ↑ → plasma free fatty acids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q
  1. •β2-Receptor mediated effects (5)
  2. α2-Receptor mediated effects (3)
A
  1. β2-Receptor mediated effects
  • oBronchodilation
  • odilation of arteries in skeletal muscle
  • o↑ glycogenolysis and gluconeogenesis
  • o↑ insulin secretion
  • orelaxation of uterus
  1. α2-Receptor mediated effects (generally sympatholytic)
  • o↓ sympathetic outflow from Central Nervous System (CNS)
  • o↓ NE release (peripheral & CNS)
  • o↓ insulin secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Agonists and antagonists at adrenergic receptors (and drugs)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Autonomic receptors in the Eye clinical importance (adrenergic and cholinergic)

  • Iris dilator
  • Iris Sphincter
  • Ciliary processes
  • Ciliary muscles
  • Conjunctivae blood vessels
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Therapeutic indications of adrenergic agonists for eye therapy (idnetify receptor and ocular use)

  • Phenylephrine
  • Apraclonidine
  • Brimonidine
  • Cocaine
  • Hydroxy amphetamine
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Therapeutic indications for β antagonists for Eye therapy (identify receptor and ocular use)

  • Betaxolol
  • Carteolol
  • Levobunolol
  • Metipranolol
  • Timolol
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Describe the cause and 3 effects in the following

  • Horner’s Cocaine and Hydroxyamphetamine
A

·Loss of Sympathetic Innervation to the Eye Results in:

  • Miosis: Loss of Iris Dilator Function
  • Ptosis (Mild Lid Droop): Loss of Mueller’s Muscle Function
  • Anhydrosis (Above Orbit, Forehead): Loss of Sweat Gland function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

How to know someone has Horner’s syndrome (2 drugs)

  • what drug do you give to diagnose and what is the effect (cause dilation in normal eye but nothing in the horner’s eye)
  • second drug that Differentiates Pre or Post Ganglionic Horner’s Syndrome
A

Cocaine MOA: (Typically replaced with Apraclonidine now)

  • Prevents reuptake of NE that has been released at the synaptic junction between the Sympathetic Post-Ganglionic Neuron and the Iris Dilator:
  • Normal Eye: Causes DILATION (Increased Iris Dilator Function)
  • Horner’s Eye: Causes NOTHING (No Nerve Activity: No NE in Synapse)

Hydroxyamphetamine (Stimulate Release of NE)

  • Differentiates Pre or Post Ganglionic Horner’s Syndrome
  • MOA: Causes release of NE from the presynaptic axon terminals of the Post-ganglionic Neuron on to the Iris Dilator
  • Preganglionic: Pupil DILATES from Topical Hydroxyamphetamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Preganglionic vs postganglionic lesions in horner’s

**Hydroxyamphetamine (Stimulate Release of NE)

A
  • Pre-ganglionic Lesions can be serious:
    • Pancoast’s Tumor: Tumor of Apex of Lung
    • Thoracic Aortic Aneurysm ◦ S/p Carotid Endarterectomy
  • Postganglionic: NO Pupil Dilation from Topical Hydroxyamphetamine
    • Post-ganglionic Lesions typically less serious, but NOT always:
      • Goiter
      • Cavernous Sinus Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Unique xters of CNS

A
  • Protective bony enclosure
  • Autoregulation of cerebral blood flow
  • Metabolic substrate requirements
  • No conventional lymphatic system
  • Special cerebrospinal fluid circulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

CNS cells (7)

A
  • neurons
  • astrocytes
  • oligodendrocytes
  • ependymal cells
  • microglia
  • choroid plexus epithelial cells
  • Schwann cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Identify CNS cells

  • •Postmitotic (Permanent)
  • •Vary in: Structure, size, function, neurotransmitter used, metabolic requirements etc.
  • •Selective vulnerability

**How do these CNS cells react to injury

A

Neurons

Neuronal reactions to Injury

  • •Acute Neuronal Injury (“Red Neuron”)
  • •Necrosis
    • liquefactive
  • •Subacute and chronic injury (Degeneration)
  • •Axonal Injury
  • •Neuronal Inclusions
  • •Intracytoplasmic Deposits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

identify acute neuronal injury

  • •12-24 h after irreversible injury due to:
    • •Hypoxic/Ischemic Insult -OR-
    • •Infectious Insult -OR-
    • •Toxic Insult
  • •Morphology
    • •Cell body shrinks
    • •Pyknosis of nucleus
    • •Cytoplasm intensely eosinophilic
A

RED NEURON

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Subacute and Chronic Neuronal Injury (Degeneration)

  • examples of condition
  • morphology
A
  • •Neuronal death over long duration
    • •e.g., ALS
  • •Morphology
    • •Cell loss, often selective – hard to detect at first
    • •Reactive gliosis – first sign
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q
  • Dispersion of Nissl Substance to the periphery (Central Chromatolysis) (II)
  • Rounding-up (III)
  • Peripheral displacement of nucleus (III)
  • Cell death (IVa) OR Cell recovery (IVb)
A

Axonal Sprouting after axonal injury / transection

  • Axonal Sprouting of proximal axon
  • Distal axon undergoes degenerative changes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Identify CNS cells

  • •Aging – Intracytoplasmic lipofuscin,
  • •Genetic Disorders
  • •Viruses
    • •Intranuclear
      • •Herpes (Cowdry A Inclusion)
    • •Intracytoplasmic
      • •Rabies (Negri Body)
    • •Intranuclear and intracytoplasmic - CMV

*****Identify neuronal intracytoplasmic deposites in 3 degenerative diseases

A

Neuronal Inclusions

Intracytoplasmic deposits

  • •Alzheimer Disease
    • •Neurofibrillary Tangles
  • •Parkinson Disease
    • •Lewy Bodies
  • •Creutzfeldt-Jacob Disease
    • •Abnormal vacuolization
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

CNS cells

types of glial cells (2)

A
  • •Macroglia
    • •Astrocytes (Barrier Function; GLIOSIS)
    • •Oligodendrocytes (Myelin)
    • •Ependymal Cells (Line Ventricles)
  • •Microglia (Fixed Macrophage)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Identify CNS cells

  • •Found in BOTH Gray & White Matter
  • •BARRIER function, supply nutrients, act as a buffer, detoxifier, insulator
  • •Reaction to injury - Repair and scar
    • •Gliosis – non-neoplastic proliferation
      • •Most important histopathologic indicator of CNS Injury
      • •BOTH hypertrophy and hyperplasia
      • •Stains for GFAP (glial fibrillary acidic protein)
    • •Rosenthal Fibers – thick, eosinophilic
      • •Long Standing Gliosis
      • •Cerebellar Pilocytic Astrocytoma
A

Astrocytes

  • •Cellular Swelling
    • •Failure of cell’s pump system in hypoxia, hypoglycemia, toxins, Creutzfeldt-Jakob Disease
  • •Corpora Amylacea (polyglucosan body)
    • •Concentrically lamellated
    • •Indicates degenerative change
    • •↑ with age
  • •Alzheimer type II astrocyte – long-standing hyperammonemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Identify CNS cell

  • Form myelin
  • Injury
  • •Seen in demyelinating disorders
  • •Viral nuclear inclusions may occur in Progressive Multifocal Leukoencephalopathy
A

Oligodendrocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

CNS cels

  • Line ventricles
  • CMV may cause
  • •Extensive ependymal injury
  • •Viral inclusions
A

Ependymal cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

CNS cells

  • •Mesoderm-Derived
  • •Fixed MACROPHAGE System
  • •Responds to Injury by
    • •Proliferation
    • •Elongating nuclei - Rod Cell
    • •Aggregate around necrotic tissue -
    • Microglial Nodules
    • •Engulf dying neurons - Neuronophagia
A

Microglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

•Vasogenic Edema ( ↑ intercellular fluid, most common)

  • •Infections, trauma, tumors, metabolic
  • •Due to
    • •Capillary damage –OR–
    • •Disrupted blood-brain barrier –OR–
    • •Permeability of new vessels (Tumors)
  • •Resorption impaired because of paucity of lymphatics
A

Cerebral Edema; Increased “brain volume” (in a closed space)

  • •Cytotoxic – ↑ intracellular fluid
    • •Seen in cell membrane injury, e.g. ischemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

CSF review

  • found where
  • secreted by?
  • how they flow?
  • absorbed?
A

CSF

  • Subarachnoid space
  • •SECRETED: Choroid Plexus
  • •FLOW: Lateral Ventricles to Foramen of Munro into 3rd Ventricle then through Cerebral Aqueduct (Aqueduct of Sylvius) in Midbrain then into 4th Ventricle then through Foramina of Luschka and Magendie into the Subarachnoid Space and then to Superior Sagittal Sinus.
  • •ABSORBED: Arachnoid Villi of Superior Sagittal Sinus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Identify condition

  • •Excessive CSF in ventricular system
  • •Dilated Ventricles
  • •Causes:
    • •Obstruction of Flow
    • •Failure of resorption
    • •Increased Secretion: Neoplasm of Choroid Plexus
A

Hydrocephalus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Identify type of hydrocephalus

  • CSF does NOT pass into subarachnoid space

**congenital vs acquired causes

A
  1. Non-Communcating Hydrocephals
  • •CSF does NOT Pass into Subarachnoid Space
  • •Congenital Causes:
    • •Aqueductal Stenosis or Atresia
    • •Dandy-Walker Syndrome
  • Acquired Causes:
    • •Neoplasms and cysts
    • •Gliosis of aqueduct
    • •Obstruction of 4th ventricle opening
    • •Organized subarachnoid hemorrhage at base of brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Identify type of hydrocephalus

•CSF Flows Out of Ventricular system BUT

  • •Excess CSF -OR-
  • •Flow obstructed in subarachnoid space -OR-
  • •Reabsorption is reduced

**Causes

A

Communicating Hydrocephalus

  • Choroid Plexus Papilloma ( ↑ Secretion)
  • •Deficient Absorption of CSF
    • •Dural sinus thrombosis
    • •Organized subarachnoid hemorrhage
    • •Organized meningitis
    • •? Deficiency of arachnoid villi
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Identfi type of hydrocephalus

  • UNCOMMON
  • Slow dilation of ventricles due to cerebral atrophy
  • •Free flow of CSF

***What is the triad??

A

Normal Pressure Hydrocephalus (Hydrocephalus ex vacuo)

  • Dementia, gait disturbance, incontinence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

ICP

  • definition (CSF pressure greater than?) what position?
  • common cause of?
  • complication?
  • Etiology of increased ICP
A

ICP (Increased intracranial pressure)

  • •Definition: CSF pressure >200mmH2O (>20mm Hg) in the Lateral Decubitus Position
  • •Common cause of neurological sx
  • •May cause death from herniation
  • Etiology of Increased ICP
    • •Usually mass effect
      • •Diffuse – cerebral edema
      • •Local – tumor, abscess, hemorrhage
    • •Obstructive (non-communicating) hydrocephalus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Type of brain herniation

  • •Due to unilateral expansion of cerebral hemisphere
  • •Displace cingulate gyrus under falx cerebri
  • •Compresses anterior cerebral artery
A

SUPRATENTORIAL Herniation:

  • Subfalcine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Type of brain herniation

  • Uncinate Gyrus of Temporal Lobe through the Tentorial Opening
  • •3rd Cranial nerve (Unequal Pupils)
  • •Compress contralateral cerebral peduncle – ipsilateral hemiparesis
  • •Duret Hemorrhage may occur (in midbrain & pons)
A

•TRANSTENTORIAL Herniation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Type of brain herniations

  • Cerebellar Tonsils through Foramen Magnum
  • Medulla Compressed (Cardiorespiratory center) → DEATH
  • Can occur when there is ↑ ICP AND lumbar puncture done
A

•TONSILLAR Herniation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q
  • Identify clinical signs/symptoms of increased ICP (3)
  • What procedure is contraindicated when pt has increased ICP
A

Increase ICP signs

  • •Headache
  • •Vomiting
  • •Papilledema

•Do NOT do Lumbar Puncture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Treatment of increased ICP

  • what can yoe remove if possible
  • what will decompress 3rd ventricle
  • how to treat cerebral edema (2 drugs and 1 equipment)
A
  • •Remove Mass, if present/possible
  • •Shunt to decompress 3rd ventricle
  • •Treat Cerebral Edema
    • •Mannitol
    • •Corticosteroids
      • •Stabilize Blood-Brain Barrier
      • •Decrease Cerebral Edema
  • •Mechanical ventilation

Hypoxia and hypercapnia increase blood circulation to brain, O2 and increased respiratory rate improve hypoxia and hypercapnia (useful in trauma) May not actually be effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

compare and contrast neuropathologic entities (5)

A
  • bacterial meningitis
  • tuberculous/mycobacterial meningoencephalitis
  • viral meningoencephalitis
  • fungal meningitis
  • neurosyphilis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

CNS infection

Acute meningitis (Leptomeningitis)

  • Identify 4 routes of infection. ** What is major NUMBER 1 ROUTE
A
  1. Bloodstream (hematogenous) is #1
    a. Primary entry site:
  • 1) Respiratory tract (N. meningitides, H. influenza, S. pneumoniae,C. neoformans, many viruses)
  • 2) Skin (neonatal meningitis)
  • 3) Intestine (enterovirus)
  1. Direct implantation
  • a. Skull fractures
  • b. Iatrogenic – surgery, lumbar puncture, etc.
  • c. Congenital malformations – e.g. meningomyelocele
  • d. Through the intact CRIBIFORM plate (free living amebas)
  1. Local extension – otitis media, mastoiditis or frontal sinusitis, infected tooth, cranial or spinal osteomyelitis
  2. Peripheral nervous system into CNS – rabies, herpes zoster, etc.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Acute vs bacterial meningitis (classification by etiology)

  • which can be rapidly fatal
  • how do neonates get acute bacterial
  • cause of acute bacterial in neonates vs children (up to 5 yars) vs adolescents vs older vs all ages
  • what cause viral meningtis
A
  1. Acute BACTERIAL meningitis can be rapidly fatal
  • a. In U.S.A. 2000 deaths/yr
  • b. Neonatal (passage through the birth canal)
    • 1) Escherichia coli
    • 2) Streptococcus agalactiae (a group B streptococcus)
  • c. Children up to 5 years of age
    • 1) Streptococcus pneumonia
    • 2) Neisseria meningitidis
    • 3) Haemophilus influenza type b was most common but H. influenza cases in this age group declined 99% from 1989 to 2000 since vaccine was introduced in 1990
  • d. Adolescents: Neisseria meningitidis
  • e. Older, debilitated, immunosuppressed: Listeria monocytogenes and gram-negative bacilli
  • f. All ages: Streptococcus pneumoniae
  1. Acute VIRAL meningitis
  • a. 90% occur in patients under 30 years of age
  • b. Rarely causes death
  • c. Mild, benign course
  • d. Enteroviruses: Echovirus, coxsackievirus, nonparalytic poliomyelitis – 80% of cases
  • e. 10% develop meningitis when they seroconvert in HIV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Cause of acute bacterial meningitis based on agegroup

  • newborns (3)
  • infants and children (3)
  • Adolescents and young adults (3)
  • Older adults (3)
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Pathology of meningitis

  • Gross
  • microscopy
A
  1. Gross: Leptomeninges are congested and covered by exudates (yellow-white)
  2. Microscopic:
  • a. Hyperemia
  • b. Fibrin
  • c. Inflammatory cells
    • 1) Bacterial: neutrophils
    • 2) Viral: lymphocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

clinical presentation of meningitis (5)

A
  1. Present with fever, headache, neck pain and vomiting
  2. PE: Neck stiffness; Kernig sign (pain with straight leg raising) both due to nerves passing across the inflamed meninges
  3. Bacterial meningitis is serious due to risk of death
  4. Viral meningitis is usually mild and self-limited
  5. Waterhouse-Friderichsen syndrome; meningitis-associated septicemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Identify clinical presentation of meningitis

a. Meningitis-associated septicemia
b. Hemorrhagic infarction of adrenal glands

  • 1) Hypotension and shock
  • 2) Petechiae (pin point hemorrhage) or purpura (bruise like) from DIC

c. Most common with meningococcal or pneumococcal meningitis

A

Waterhouse-Friderichsen syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

How to diagnose meningitis

  • acute vs viral findings in the CSF
A

Diagnosis
1. Examine CSF by lumbar puncture

  • a. Cell count
  • b. Chemistry (protein, glucose, chloride)
  • c. Culture and Gram stain
  1. Findings
    * *a. Bacterial**
  • 1) Cell count – neutrophils
  • 2) Chemistry: protein is HIGH, glucose is VERY LOW
  • 3) Culture is positive in 90%

b. Viral

  • 1) Cell Count – lymphocytes
  • 2) Chemistry: protein is slightly elevated, glucose is NORMAL
  • 3) Viral cultures are positive in 70%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Treatment of meningitis

bacteria vs viral

A
  1. Antibiotics for bacterial
  • a. Until cultures are back from the lumbar puncture choose antibiotics based on
    • 1) Chemical examination (protein, glucose)
    • 2) Type of cells present
    • 3) Gram stain
  • b. Start antibiotics FIRST, LP within 30 minutes
  1. Viral meningitis is usually supportive therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Infection of brain parenchyma

**Identify focal suppurative infections (2)

A
  1. Brain Abscess
  2. Subdural empyema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Infection of brain parenchyma - cerebral/brain abcess

  • Cavity
  • Etiology
A

Cavity; pus: Liquefied brain and PMN’s

Etiology

  • a. Streptococci and staphylococci most common, anaerobes common
  • b. Complications of other diseases
  • 1) Chronic suppurative infections of the middle ear and mastoid air spaces and paranasal sinuses (local extension)
    2) Infective endocarditis – often develop small and multiple abscesses
    3) Right-to-left shunts (e.g. congenital cyanotic heart disease)
    4) Tooth extraction
    5) Suppurative lung disease (RARE cause); leads to parietal lobe abscesses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Pathology of brain abcess

A

a. Appears as mass lesion
b. Liquefied center with pus surrounded by
c. Fibrogliotic wall - thickness depends on duration
d. Adjacent brain: frequent vasogenic edema
e. Most common sites: Frontal lobe, parietal lobe, and cerebellum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Clinical features and diagnosis and treatment of the following

A

BRAIN ABCESS

  1. Clinical features & diagnosis
  • a. Space-occupying lesion (increased intracranial pressure: headache, vomiting and papilledema)
  • b. Focal neurologic signs – depends on location
  • c. Evidence of infection (fever, elevated erythrocyte sedimentation rate, weight loss in chronic cases)
  • d. If untreated may cause death by increased intracranial pressure or rupture into ventricles
  • e. Dx’d clinically, confirmed by CT or MRI scan
    • 1) Lumbar puncture dangerous, risk of herniation
    • a) CSF normal -or-
    • b) Mild increases in protein, neutrophils and lymphocytes
    • c) Cultures: may or may not grow
  1. Rx – surgical evacuation (drain abcess), followed by antibiotics. Former high mortality rate has been reduced to 5-10%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

identify CNS infection

  1. Collection of pus in the subdural space
  2. Source is bacterial or fungal (less common) infection of skull bones or air sinuses
  3. Mass effect
  4. Can cause a thrombophlebitis of bridging veins → venous occlusion → infarction of brain
  5. Sx
  • a. Early – fever, headache, neck stiffness
  • b. Later (untreated) – focal neurologic signs, lethargy, coma
  1. Rx – surgery & antibiotics
A

Subdural empyema

**Thrombophlebitis (inflammation of veins which gets prothrombotic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Identify chronic bacterial meningoencephlitis (3)

A
  • TB (tuberculosis)
  • Neurosyphilis
  • Neuroborreliosis (Lyme Disease)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Viral meningoencephalitis

  • clinical features
  • Treatment
A
  1. Clinical Features
  • a. Acute onset with fever, headache, and signs of brain dysfunction
  • b. Convulsions may occur
  • c. May have papilledema
  • d. May have meningeal inflammation causing neck stiffness and CSF like viral meningitis
  • e. Dx by clinical picture
  • f. Lumbar puncture may give etiology
  1. Rx
  • a. Supportive
    • 1) High dose corticosteroids to treat cerebral edema
    • 2) Anti-virals
  • b. In severe encephalitis
    • 1) Mortality HIGH
    • 2) Frequently left with permanent neurologic deficits due to irreversible neuronal necrosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

CSF finding in TB vs bacteria meningitis vs viral meningitis

  • Cell count
  • Protein
  • Glucose
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Identify clinical presentation and complication of the following chronic bacterial meningoencephalitis

  1. Morphology
  • a. Macroscopic; Gelatinous or fibrinous exudates at base of brain
  • b. ENTIRE brain and meninges involved. Microscopic;
    • 1) Lymphocytes, plasma cells, macrophages
    • 2) In fully developed cases: caseating granulomas, caseous necrosis, giant cells
    • 3) Obliterative arteritis of arteries crossing the subarachnoid space
A

TB (Tuberculosis); seeded from a pulmonary infection

  1. Clinical
  • a. Sx – headache, malaise, mental confusion, vomiting
  • b. Dx – Lumbar puncture
    • 1) Cell count – BOTH neutrophils and lymphocytes
    • 2) Chemistry: protein is VERY high, Glucose is low or normal
    • 3) Acidfast stain positive (may see mycobacterium)
    • 4) Mycobacterial culture is positive; takes 2 weeks to grow
  • c. Rx – long term antibiotics
  1. Complications
  • a. Arachnoid fibrosis in long-standing cases, resulting in hydrocephalus
  • b. Obliterative endarteritis → arterial occlusion → infarction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Chronic bacterial meningoencephalitis - Neurosyphilis

  • What percent progress when left untreated
  • 3 major forms
  • Treatment (that stop progression)
A
  1. 10% of untreated cases progress to teriary or neurosyphilis
  2. Three major forms
    * *a. Meningovascular neurosyphilis**
  • 1) Involves base of brain, cerebral cortex, spinal leptomeninges
  • 2) Obliterative endarteritis and perivascular inflammation with plasma cells and lymphocytes
  • 3) Cerebral gummas (masses of plasma cells)

b. Paretic neurosyphilis

  • 1) Invasion of brain by Treponema pallidum
  • 2) Progressive loss of mental and physical functions
  • 3) Loss of neurons, increased microglia, gliosis and iron deposits in cerebral ctx

c. Tabes dorsalis

  • 1) Damage to sensory nerves in dorsal roots by spirochetes
  • 2) Ataxia, loss of pain sensation and absence of deep tendon reflexes
  • 3) Loss of axons and myelin in dorsal columns

3. Penicillin will prevent the progression of developed neurosyphilis but will NOT reverse the damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Identify type of neurosyphilis

1) Involves base of brain, cerebral cortex, spinal leptomeninges
2) Obliterative endarteritis and perivascular inflammation with
plasma cells and lymphocytes
3) Cerebral gummas (masses of plasma cells)

A

Meningovascular neurosyphilis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Identify type of neursyphilis

1) Invasion of brain by Treponema pallidum
2) Progressive loss of mental and physical functions
3) Loss of neurons, increased microglia, gliosis and iron deposits in cerebral ctx

A

Paretic neurosyphilis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Identify type of neurosyphilis

1) Damage to sensory nerves in dorsal roots by spirochetes
2) Ataxia, loss of pain sensation and absence of deep tendon reflexes
3) Loss of axons and myelin in dorsal columns

A

Tabes Dorsalis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Identify chronic bacterial meningoencephalitis

  1. Highly variable symptoms: aseptic meningitis, facial nerve palsies, mild encephalopathy
  2. Microscopic: microglial cells and scattered organisms
A

Neuroborreliosis (Lyme Disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Identify viral meningoencephalitis (9)

A
  1. Arthropod-borne viral encephalitis
  2. Herpes simplex encephalitis
  3. Varicella Zoster
  4. CMV (cytomegalvirus)
  5. Poliomyelitis (poliovirus)
  6. Rabies
  7. HIV encephalopathy
  8. PML (progressive multifocal leukoencephalopathy)
  9. SSPE (Subacute sclerosing panencephalitis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Viral meningoencephalitis

General points

  • parenchymal infecion of brain associated with?
  • define tropism
  • pathology
A
  1. Parenchymal infection of brain with associated meningeal inflammation +/- spinal cord involvement
  2. “Tropism” – some viruses infect certain cells and/or certain areas of brain
  3. Pathology
  • a. Usually blood-borne
  • b. Affects brain
    • 1) Perivascular and parenchymal mononuclear infiltrates (lymphocytes, plasma cells, macrophages)
    • 2) Microglial nodules
    • 3) Neuronophagia
    • 4) May be specific inclusion bodies
    • 5) Severe cases, hemorrhage occurs
    • 6) Cerebral edema
  • c. Result: cerebral dysfunction and increased intracranial pressure (HA, vomiting, papilledema)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Identify viral encephalitis

a. Cause epidemic encephalitis
b. In Western hemisphere – Eastern and Western equine, St. Louis, LaCrosse, West Nile, Venezuelan
c. CSF: neutrophils first then lymphocytes, protein elevated, glucose normal
d. Histology: Perivascular lymphocytic cuffing, necrosis with
neuronophagia, microglial nodules
e. Serious morbidity and high mortality

A

Arthropod-borne viral encephalitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Identify viral encephalitis (incidence) based on pathology, dx and treatment

b. Pathology

  • 1) Infects the temporal and inferior frontal lobes and orbital gyri
  • 2) Necrotizing, hemorrhagic acute encephalitis
  • Intranuclear cowdry A inclusion bodies
  • 3) May be rapidly fatal (CAUSE DEATH) or
  • 4) May be subacute, developing over 4-6 wks (usually HSV-1)

c. Dx:

  • 1) PCR of CSF***
  • 2) Brain bx, necessary for dx prior to PCR
    • a) Intranuclear Cowdry A inclusions in neurons and glia
    • b) EM, immunohistochemical, in situ hybridization –demonstrates the virus in most cases

d. Rx: if given early, antiviral agent (acyclovir)

A

Herpes Simplex encephalitis

a. Incidence (occurs in 2 groups)
1) Children and young adults, may be any age

  • a) Only 10% have h/o prior herpes
  • b) Usually HSV-1
  • c) HSV-1 is most common cause of sporadic encephalitis in US

2) Neonates

  • a) Delivery in a woman with active herpes genitalis
  • b) Usually HSV-2
  • c) Do caesarian section
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

identify viral CNS infection

a. Rare cause of encephalitis in immunosuppressed pts
b. Due to reactivation of latent virus
c. Lesions show demyelination then necrosis

A

Varicela-Zoster

  • Causes Shingles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Identify viral CNS infection

a. The fetus is infected in the last trimester due to transplacental infection (TORCH)
* 1) Causes periventricular necrosis and calcification resulting in microcephaly
b. Also occurs in immunocompromised, esp. AIDS

  • 1) Prior to ART (antiretroviral therapy) was the most common opportunistic viral pathogen in HIV/AIDS pts
  • 2) Now rare in HIV/AIDS
  • 3) Most often occurs as subacute encephalitis
  • 4) Predilection for paraventricular subependymal regions
A

CMV (Cytomegalovirus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Identify viral CNS infection

a. Infects via fecal-oral route
b. Causes a mild gastroenteritis, invades CNS in few patients (via bloodstream)
c. Selectively infects

  • 1) Meninges (Acute lymphocytic meningitis)
  • 2) Anterior horn motor neurons of the spinal cord – Perivascular lymphocytic cuffing and neuronophagia

d. Clinically

  • a) Flaccid paralysis, muscle wasting, hyporeflexia (asymmetrical)
  • Identify the condition???????
    • 1) 25-35 yrs after initial illness
    • 2) Weakness, loss of muscle mass, pain
A

Poliomyelitis (poliovirus)

  • Acute paralysis
    • Asymmetircal
    • Flaccid muscle paralysis
    • Muscle wasting
    • Hyporeflexia (can sometimes affect the diaphragm)

**Post polio syndrome

  • 1) 25-35 yrs after initial illness
  • 2) Weakness, loss of muscle mass, pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Identiy viral CNS infection

f. Clinical

  • 1) Fever, malaise, paresthesias around bite site (even after the bite/wound is healed)
  • 2) CNS hyperexcitability even generalized convulsions stimulated by the slightest sensations
  • 3) Contracture of pharyngeal muscles – drooling and foaming at the mouth
  • 3) Death is essentially inevitable. (some people tho have survived)

g. Rx: Prevention and pre- or post-exposure vaccine prophylaxis

A

Rabies (aka Hydrophobia - fear of water. Seen first in dogs with rabies that couldn’t drink water)

  • a. Rare in humans
  • b. From bite of infected mammal, rabies virus ascends along peripheral nerves to CNS
  • c. Incubation: 1-3 months (longer for virus to travel up nerve that bloodstream)
  • d. CNS infection causes severe neuronal degeneration and inflammation
    • 1) Midbrain
    • 2) Medulla
    • 3) Basal ganglia
  • e. Dx: Diagnostic eosinophilic intracytoplasmic inclusion bodies (Negri bodies )
    • 1) In pyramidal neurons of hippocampus or Purkinje cells (no inflammation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Identify viral CNS infection

  • Less common now than prior to the availability of HAART (2 types)
A

HIV Encephalopathy

  • HIV aseptic meningitis (no bacteria)
    • 1) 1-2 weeks after seroconversion
      2) 10% of patients
      3) Virus in CSF and antibodies in serum
  • HIV meningoencephalitis
    • 1) Morphology
    • a) Virus gains access to CNS via infected macrophages
      b) Chronic inflammation
      c) Microglial nodules with multinucleated giant cells
      d) May see foci of necrosis and gliosis
      e) Virus found in CD4+ macrophages and microglia, not in neurons or oligodendrocytes
    • 2) Clinical
      a) Mild to severe cognitive changes (HIV associated dementia)
    • b) Related to number of activated microglia in the brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Identify viral CNS infection

a. Etiology: Reactivation of the JC virus (a polyoma virus) in setting of immunosuppression. (everyone gets infected with JC virus by age 14)
b. Seen in

  • 1) Chronic lymphoproliferative and myeloproliferative diseases
  • 1) HIV/AIDS
  • 2) Cancer chemotherapy

c. Pathology

  • 1) Infects oligodendrocytes
  • 2) Widespread focal demyelination of white matter involving entire brain
  • 3) Giant atypical astrocytes
  • 4) Enlarged oligodendrocytes with intranuclear inclusions

d. Dx: CT and MRI show multifocal demylinated lesions in white matter. Grey matter has no myelin
e. Clinical

  • 1) Acute, rapidly progressive illness with multifocal cerebral dysfunction
  • 2) Mortality rate is high
A

Progressive Multifocal Leukoencephalopathy (PML)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Identify viral CNS infection

a. RARE especially since initiation of measles vaccine (MMR vaccine)
b. Children and adults months to years after measles
c. A persistent measles viral infection
d. Pathology

  • 1) Widespread gliosis
  • 2) Myelin degeneration
  • 3) Intranuclear inclusions
  • 4) Variable inflammation
  • 5) Neurofibrillary tangles

e. Clinical

  • 1) Cognitive decline
  • 2) Spasticity of limbs
  • 3) Seizures
  • 4) Relentless, causes death in 1 to 2 years from onset
A

Subacute Sclerosing Panencephalitis (SSPE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Identify the following body part

gross collection of convoluted bulges referred to as gyri which are separated from each other by involutions called sulci

**various parts?

A

Cerebral Cortex

Lobes are separated by the major sulci

    1. A sulcus termed the lateral fissure (of Sylvius) separates the frontal and temporal lobe
    1. The central sulcus separated the frontal and parietal lobe
      * a. On the medial aspect of the brain the cingulate sulcus separates the frontal and parietal lobes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Understand term dominant hemisphere and its implication on language localization

A
  • Most people (80-85%) are right-handed which implies that the left hemisphere is dominant and houses language production and comprehension.
      1. Many left handed people also have left hemisphere dominance (70-85%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Define and localize Wernicke and Broca Type Asphasia

A

There are two main areas involved in the production and comprehension of language:
a. Broca’s Area is located in the frontal lobe and sits adjacent to the primary motor cortex.

  • i. Damage to the Broca’s area by stroke or other structural defect causes impaired language production with intact language comprehension.

b. Wernicke’s area is located in the superior temporal gyrus of the temporal lobe

  • i. Damage to the Wernicke’s area causes impaired language comprehension with intact language production in some sense. Because one does not comprehend the content of language, there language in-turn also makes no sense but has normal fluency and prosody (rhythm and emotional tone inflections of speech)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Lobes of the brain

largest lobe of the brain and controls movement of the contralateral side of the body. It is comprised of many eloquent areas which will described below ?

**WHich area is just anterior to the main motor strip? damage results in?

A

FRONTAL LOBE

Premotor cortex

    1. This area is just anterior to the main motor strip.
    1. Damage results in apraxia (disruption of planning of patterning and execution of learned motor movements).
      * a. An example of ideomotor apraxia: A 76 y/o wood worker suffers a stroke. In follow-up he states he can no longer use his tools. In testing you hand him a hammer and he can readily tell you the function of the tool and its name but cannot perform the proper movements to use it.
    1. Damage in the region of the premotor cortex often affects the frontal eye field as well
      * a. Lesion to the frontal eye field results in impairment of horizontal gaze to the contralateral side. Patients have forced eye deviation toward the side of the lesion.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

Parts of frontal lobe

  1. part that results in apraxia? what is apraxia?
  2. located in the anterior frontal lobe and used in panning intellectual and emotional aspects of behavior
  3. This aspect of the frontal lobe is located anterior to the central sulcus
A
  1. Premotor cortex
    • ​​Damage results in apraxia (disruption of planning of patterning and execution of learned motor movements).
    • Damage also affect frontal field; patients have forced eye deviation TOWARD side of lesion
  2. Prefrontal Cortex
  3. Located in the anterior frontal lobe
  4. Used in planning the intellectual and emotional aspects of behavior
    a. Some patients who suffer lesions to the prefrontal cortex have symptoms of apathy and abulia (dramatic lack of motivation).
  5. Motor Cortex
  6. This aspect of the frontal lobe is located anterior to the central sulcus
  7. It controls motor functions and is designed in the form of the motor homunculus detailed below:
    a. Patients having lateral frontal lobe stroke tend to have greater facial weakness where as those with high frontal lobe infarcts have more arm and leg weakness.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

the second largest lobe of the brain and interprets sensory of the contralateral side of the body. It is also comprised of many eloquent areas which will be described below

**2 parts of parietal lobe

  • area posterior to sulcus
  • area posterior to somatosensory. defect result in?
A

PARIETAL LOBE

Primary somatosensory cortex

    1. This aspect of the parietal lobe is located posterior to the central sulcus
    1. It controls the interpretation of somatosensory stimuli (light touch, pressure, two point discriminative touch, vibration, position sense, and temperature) and is oriented in the sensory homunculus below:
      * a. Lesion to this aspect of the parietal lobe results in contralateral impairment of all somatosensory input types

iii. Posterior parietal association cortex

    1. This region is posterior to the somatosensory cortex.
    1. When lesioned it also presents with symptoms of apraxia (described above under “premotor cortex”)
    1. A lesion in this location may also result in the inability to recognize objects based on touch alone- “astereognosia”.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Part of parietal lobe

The sensory homunculus is represented in this Claymation character to further emphasize the cortical space occupied for each sensory area

***Excessive areas?

A

**note that hands and mouth have an excessive area of dedicate cortical tissue to process the immense amount of neural information from the numerous nerve endings in these areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

the very medial aspect of the occipital lobe adjacent to the interhemispheric fissure
b. It is designed in a way the each part of the retina is schematically arranged onto the cortical surface

A

Primary visual cortex

  • a. This area is on the very medial aspect of the occipital lobe adjacent to the interhemispheric fissure
  • b. It is designed in a way the each part of the retina is schematically arranged onto the cortical surface
    • i. When one small area is damaged by stroke, the corresponding retinal information is lost resulting in a scotoma (blind spot)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Be able to recall the visual pathway and localize visual field cuts

A

A. Right Optic nerve damgae; ipsilateral blindness in right eye

B. Optic chaism; Bitemporal hemianopsia

  • Caused by pituitary tumor, MS, berry aneurysm

C. Optic tract; homonymous hemianopsia

D. Right meyer’s loop; left upper quadrantonosia

E. Occipital cortex? ; caused by PCA infarction (right)

  • Left homonymous hemianopsia with macula sparing.
  • If MCA (middle cerebral arteyr is lost, there will be no macula sparing)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Visual case

62 y/o man presents with his neighbor to the ED because of presumed vision problems over the last two days. The neighbor noted he required holding onto objects as he walked through his home and has had multiple trips and falls on his walkway and steps. The man states there is nothing wrong and that he could see normally. There was no clear blink to threat. On exam he was unable to count fingers or even identify large objects. Pupillary light exam and fundoscopic examination was unremarkable. Imaging showed the following:

A

•Patient is exhibiting classic symptoms for Anton’s Syndrome

•Anton’s Syndrome- cortical blindness due to lesion of both occipital lobes (including primary visual cortex).

•The patient exhibits profound anosognosia (lack of regard for deficit) which is common in this syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Identify

  • located at the borders of the occipital lobe with the temporal and parietal lobes
    • Its function is high level interpretation of visual input including, but no limited to, motion and depth perception, spatial representation and color differentiation amongst other high level processes.

***Identify what happens when you have lesions in this area (3)

A

Visual Association Cortex; lesions in this area cause;

  • Achromatopsia-complete loss of color appreciation in the contralateral visual field
  • Prosopagnosia-inability to recognize faces (they retain the ability to identify people based on voice)
  • Visual Agnosia- inability to recognize visual patterns, including objects, without having a visual field cut.
    1. An example of visual agnosia is having a patient look at a pair of glasses and they describe seeing a bar and two circles but cannot identify the object as glasses.
100
Q

identify lobe

  • located below the frontal and parietal lobes and houses very important structures for the integration of memory and for the production of the emotional response
  • what is the major cortex it houses?
    • damage to this cortex lead to what comdition
A

Temporal Lobe

Primary Auditory Cortex:

  1. Located deep within the lateral sulcus, the auditory association cortex occupies the two transverse gyri of Heschl.
  2. The primary auditory cortex functions to interpret sounds, including speech, and is a component of the Wernicke’s area in the dominant hemisphere.
  • a. Patients with a lesion to the area of the primary auditory cortex on the dominant hemisphere have a Wernicke’s Type Aphasia
    • i. Recall that Wernicke’s Aphasia is a receptive aphasia. Lesion resulting in this syndrome causes the inability to comprehend speech or written word. Speech production is intact but the content is nonsensical and often termed “word-salad”
101
Q

Identify

  • a. major sensory input from the ascending tracks from the spinal cord, brainstem, basal ganglia and cerebellum. One can think of this area as the main sensory relay “switch” for the brain.
  • b. It is a fairly complicated structure made up of numerous nuclei which all serve distinct functions
    *
A

Thalamus

c. The most effective way to remember the functions of various elements of the thalamus is to divide into sections where nuclei share common function ( i.e. motor input, sensory input, etc..) and to use pneumonics

102
Q

Understand basic functioning of thalamic and hypothalamic nuclei with eventual goal of memorization for testing

Thalamic nuclei; motor nuclei? sensory nuclei? visual?

Hypothalamic nuclei;

  • water balance
  • body temperature
  • blood presure
  • water balance/stress
  • shivering
  • GI tract
  • biologic clock
  • satiety
  • feeding
A

Thalamic Nuclei

  • Motor Nuclei
      1. Ventral Anterior (VA)- gets input from the basal ganglia
      1. Ventral Lateral (VL)-gets input from the basal ganglia AND cerebellum
  • Sensory Nuclei
      1. Ventral posteromedial (VPM)- input from the trigeminal nucleus (think M as Mouth)
      1. Ventral posterolateral (VPL) input from the medial lemniscus and spinothalamic tract (think L as Limbs)
      1. Medial Geniculate- input from the inferior colliculus, processes sounds (think Medial Geniculate= Music)
        * a. Auditory Pathway pneumonic “NCS LIMA”
        * i. Acoustic Nerve → Cochlea Nucleus → Superior Olive (Pons) → Lateral Lemniscus (Pons) → Inferior Colliculus (mid brain) → Medial Geniculate (thalamus) → Auditory Association Cortex
      1. Lateral Geniculate Nucleus- Input from the optic tract (think Lateral Geniculate= Light)
  • Medial Nuclear Group
    • i. Dorsal Medial Nucleus (main medial nuclei but not pictured above)- input from the limbic system- involved in memory and emotion
        1. Lesion here results in amnesia
  • Pulvinar
    • i. No true input from outside the thalamus- responsible for visual attention

Hypothalamus

  • a. The hypothalamus is also a very complicated network of hard-to-remember nuclei that have multiple afferent and efferent connections throughout the nervous system.
  • b. It is involved in hunger, thermoregulation, water balance, reproduction, and even the sleep wake cycle.
  • c. It is also highly involved in the limbic and autonomic systems and has numerous projections to the pituitary gland
  1. Paraventricular AND Supraoptic- These nuclei synthesize antidiuretic hormone and oxytocin. They function in the management of water balance.
    a. Lesion in this nuclear group results in central (central meaning from the brain, not the kidneys) diabetes insipidus
    i. Clinically appears as polyuria and excess water consumption.
  2. Satiety/Hunger
    a. Ventromedial Nucleus- satiety center. Lesion in this area makes affected individuals obese
    b. Lateral Hypothalamic Area- hunger center. Lesion in this area makes affected individuals have no desire to eat (aphagia-refusal to eat or swallow)
  3. Temperature Regulation
    a. Anterior Hypothalamic Area - senses increase in temperature and induces sweating to dissipate heat. Lesion here results in hyperthermia
    b. Posterior Hypothalamic Area-senses decrease in body temperature and induces shivering. Lesion here results in poikilothermy (body temperature will vary with environment)
  4. Circadian Rhythm
    a. Suprachiasmatic nucleus obtains visual input from the retina via the optic tract. This area sets the circadian rhythm to the day/night surroundings.
  5. Memory
    a. Mammillary bodies are part of the limbic system and critical to the formation of memory. Lesion here results in anterograde and retrograde memory impairment.
    i. Review of memory formation: Papez Circuit- memory formation (limbic system)
  6. Think H. MACE for memory formation
    a. Hippocampus → Mammillary Bodies → Anterior Nucleus of the Thalamus → Cingulate Gyrus → Entorhinal Cortex
103
Q

Case

A 56 y/o male presents to the ED with his wife for confusion. Historically she states he is a long-term drinker and regularly consumes a pint of liquor daily. On exam you find him to be somewhat combative and agitate. He has decreased horizontal and vertical eye movements appearing as ophthalmoparesis. His gait is ataxic and his reach for objects is cumbersome and inaccurate. Neuroimaging shows the following:

A
  • Patient is exhibiting classic symptoms for Wernicke’s encephalopathy (confusion, ataxia, and ophthalmoparesis).
  • Wernicke’s encephalopathy is typically seen in alcoholism and severe malnourished states and is caused by a deficiency vitamin B1 (thiamine)
  • The deficiency results in damage to the mamillary bodies and ultimately results in necrosis (as seen on the MRI). If patients survive they often suffer from Korsakoff’s syndrome (anterograde and retrograde amnesia with confabulation.
104
Q

Define (identify components)

collection of nuclei in the deep white matter and functions extensively in the motor planning and performance.

A

BASAL GANGLIA

The main components include the chief input nuclei of the basal ganglia known as the caudate and putamen (collectively termed the striatum) which receive information from the brainstem, cerebellum, thalamus and supplementary motor cortex.

The remainder of the basal ganglia includes the globus pallidus, substantia nigra and the subthalamic nucleus. The main output is to the thalamus, specifically the ventrolateral and ventroanterior nuclei (VL/VA)

105
Q

Recall the general function of the direct and indirect pathways through the basal ganglia

A
  • The basic function of the basal ganglia is to promote and inhibit movements. This is achieved through the “dreaded” direct and indirect pathways which will be reviewed below: Interestingly these two systems work to antagonize each other as one stimulates the primary cortex to cause movement and the other inhibits it.
  • i. Direct Pathway: In the simplest terms I can put it, the direct pathway takes excitatory information from the cerebral cortex (mostly the premotor area) and passes it through the striatum (caudate and putamen) to the internal globus pallidus then to the ventrolateral (VL) nucleus of the thalamus and finally back to activate the primary motor cortex where movement is stimulated. Direct Pathway = Stimulation of movement.
  • ii. Indirect Pathway: Once again excitatory information is sent from the supplemental motor area to the striatum. From there it travels to the external globus pallidus that project to the subthalamic nucleus. The subthalamic nucleus then inhibits the VL of the thalamus which does not send signal to the primary motor cortex. So no movement occurs. Indirect Pathway=Inhibits movements.
106
Q

Problems in direct and indirect pathway of basal ganglia?

3 parts of basal ganglia individual problems?

A

Problems in these pathways can result in movement disorders

  1. Lesions to specific areas of the basal ganglia result in varying movement disorders
    a. Caudate and/or putamen lesion cause chorea
    b. Subthalamic nucleus lesion induces hemiballismus
    c. Substantia nigra lesion or degeneration results in Parkinsonism.
107
Q

Case

A 57 y/o male presents to the neurology clinic for evaluation of chronic irregular limb movements which are progressively worsening. He recalls a family history of similar movement disorder in his father and paternal uncle. On exam he demonstrates bilateral choreiform movements involving the upper and lower extremity which worsen with distraction. Imaging is obtained and shown below.

A

This case is the classic presentation for Huntington’s disease (HD). HD is a neurodegenerative condition resulting in a hyperkinetic (fast irregular movements) movement disorder. Genetically there is a problem with trinucleotide expansion of CAG in the Huntington gene on chromosome 4. This disease has genetic anticipation meaning that each subsequent generation will have more trinucleotide repeats and will therefore express the disease earlier and often with more severe symptoms.

108
Q

Ferguson questions

A
  1. C
  2. D
  3. B
109
Q

Identify receptor

  • ·Found at parasympathetic effector targets
  • ·Found at sweat glands, which are sympathetic targets
  • ·Found on presynaptic neuronal membranes (suppress the release of ACh)
  • ·ACh binds to and activates muscarinic receptors
A

Muscarinic Receptors

110
Q

Effects of Muscarinic receptors

  • Cardiac vs vascular effects
  • GI effects
A

•Cardiovascular

  • oCardiac effects (direct)
    • oSA node (↓ HR), AV node (↓ conduction), atria > ventricle (↓ contractility)
  • oVascular effects
    • oVasodilation (indirect effect mediated through ↑ in nitric oxide)

•Gastrointestinal

  • oIncreased motility, relaxed sphincters, and increased secretion
111
Q

Muscarinic receptor effects

  • salivary and nasopharyngeal glands
  • urinary
  • resp tract
  • Eye
  • Sweat gland
A
  • •Salivary and nasopharyngeal glands
    • oIncreased secretion
  • •Urinary
    • omicturition
  • •Respiratory tract
    • obronchoconstriction, and increased respiratory secretions
  • •Eye
    • ocontraction of the iris sphincter → miosis
    • ocontraction of the ciliary muscle of the eye to induce accommodation for near vision
  • •Sweat gland (sympathetic effect)
    • o↑ sweating
112
Q

Muscarinic agonists - effect on if; metabolized by cholinestease? muscarinic activity? blocked by atropine? nicotinic activity? quaternary amines?

  • Ach
  • Methacholine
  • Carbachol
  • Bethanechol
  • Muscarine
  • Pilocarpine

**what do all 6 do (2)

Whats 3 have nicotinic activity? what 3 don’t

what 2 are metabolized by cholinesterases? (major one? )

what has no quaternary amines?

A

***If you have muscarinic activity means can activate ganglia?

All Muscarinic agonist have muscarinic activity and are blocked by atropine

113
Q

MoA of muscarinic agonists

Physiologic effects (organ system effects)

  • Cardiovascular (low dose vs high dose)
  • GI
  • Urinary
  • Resp tract
  • Eye
  • Glands
A

Muscarinic Agonists

  • Mechanism of action: Bind to and activate muscarinic receptors
114
Q

Clinical uses of muscarinic receptor agonist (identify the medications to use)

  1. Dx airway hyperractivity (don’t use if pt has asthma)
  2. stimulate urinary and GI tracts to reverse urinary retentiona and gastric atony
  3. Glaucoma (angle close and open angle), miosis inductions, sjogren syndrome
  4. Glaucoma, miosis induction
A
  1. •Methacholine
    • oDiagnosis of airway hyperreactivity
  2. •Bethanechol
    • oStimulate urinary and GI tracts
    • oReverse urinary retention
    • oReverse gastric atony
  3. ·Pilocarpine
    • oGlaucoma
      • oAngle closure glaucoma
      • oOpen angle glaucoma
    • oMiosis induction
    • oSjögren’s syndrome – Xerostomia (destroy tear and salivary glands)
  4. ·Carbachol
    • oGlaucoma (similar to pilocarpine)
    • oMiosis induction
115
Q

Adverse effects of muscarinic agaonists (8)

Muscarine poisoning

A

·SLUD(E) + BBB

  • S - salivation
  • L - Lacrimation
  • U - urination
  • D(E) – defecation (emesis)
  • B –bronchoconstriction
  • B – bradycardia
  • B – blurred vision (spasm of ciliary muscle)

Muscarine poisoning (mushrooms)

  • Inocybe & Ciltocybe (mushrooms)
  • SLUD(E) + BBB
116
Q

Contradincations/precautions of muscarinic receptor agonists

  • increased risk for bronchospasm
  • bradycardia and hypotension
  • GI
  • coronary blood flow
  • a fib
  • acid
A
  • •Asthma & COPD (↑ risk for bronchospasms)
  • •Bradycardia, hypotension (↓↓ bradycardia, hypotension)
  • •Compromised integrity of GI or bladder wall (↑ GI and bladder wall contractions)
  • •Coronary artery disease (↓ coronary blood flow)
  • •Hyperthyroidism (↑ risk for atrial fibrillation)
  • •Peptic ulcer (↑ acid secretion)
117
Q

Muscarinic receptor antagonist

  • MoA
  • Examples of drugs (12)
A

A.Mechanism of Action

  • ·Prevent the effects of ACh by blocking its binding to muscarinic receptors at parasympathetic (and sympathetic) neuroeffector target tissue/cells.

B. Drugs

  • •Atropine, scopolamine, tiotropium, ipratropium, benztropine, trihexyphenidyl, homatropine, oxybutynin, tolterodine, darifenacin, solifenacin, festoterodine
118
Q

Physiologic effects of muscarinic receptor antagonists

  • CV
  • GI
  • Urinary
  • Respiratory
  • Eye
  • SKin
  • CNS
A
  • •Cardiovascular
    • •Transient ↓ HR @ low dose (↑ in vagal release of ACh)
    • •↑ HR @ higher doses (direct cardiac effects)
    • •Dilation of cutaneous blood vessels (causes atropine blush)
  • •Gastrointestinal
    • •↓ tone & motility
    • •↓ secretions
  • •Urinary
    • •Urinary retention
  • •Respiratory
    • •Bronchodilation & decreased secretions
  • •Eye
    • •Cycloplegia (paralysis of the ciliary muscle of the eye). Near vision is compromised.
    • •Mydriasis (inhibition of the iris sphincter muscle)
  • •Skin
    • •↓ sweating (hyperpyrexia may result)
  • •CNS
    • •Confusion, and CNS depression
119
Q

Clinical uses of muscarinic receptor antagonists

  1. •Reverse cardiac arrest that is due to very slow heart rate (due to increased vagal tone)

•Reverse organophosphate poisoning

Reverse toxic effect from eating mushrooms containing muscarine
2. •Mydriasis induction

  1. •Extrapyramidal disease. Reverse antipsychotic medicine-induced movement disorder

Parkinson’s disease

  1. •Motion sickness

•Postoperative nausea and vomiting

  1. •bladder muscle dysfunction, overactivation leading to ↑ in urinary frequency, urgency, or urge incontinence.
A
  1. Atropine
  2. Homatropine
  3. Trihexyphenidyl and Benztropine
  4. Scopolamine
  5. Oxybutynin, tolterodine, darifenacin, solifenacin, festoterodine
120
Q

Adverse effects of muscarinic receptor antagonists (9)

A
  • ·Narrow-angle glaucoma (contraindication)
  • ·Open-angle glaucoma (use with caution)
  • ·Cardiac disease (tachycardia)
  • ·Cycloplegia
  • ·Blurred vision
  • ·Mydriasis (lead to glaucoma attack)
  • ·CNS effects (dizziness, confusion)
  • ·Xerostomia (stoppage of saliva)
  • ·Prostatic hypertrophy (provoke urinary retention)
121
Q

Effects of atropine in relation to dose

  • 0.5mg
  • 1mg
  • 2mg
  • 5mg
  • >= 10mg
A

•Old mnemonic; Red as a beet; Dry as a bone; Blind as a bat; Hot as a firestone; and mad as a hatter

  • •0.5 mg
    • •Slight cardiac slowing; dryness of mouth; inhibition of sweating
  • •1 mg
    • •Definite dryness of the mouth; thirst; accelerated heart rate; sometimes preceded by slowing; mild dilation of pupils
  • •2 mg
    • •Rapid heat rate; palpitations; marked dryness of the mouth; dilated pupils; some blurring of near vision
  • •5 mg
    • •Above symptoms are marked (rapid heart rate, blurry vision); difficulty speaking and swallowing; restlessness and fatigue; headache; dry, hot skin; difficulty in micturition; reduced intestinal peristalsis
  • •≥ 10 mg
    • •Above symptoms are more marked; pulse rapid and weak; iris practically obliterated; vision very blurred; skin flushed; hot; dry; scarlet; ataxia; restlessness; hallucinations; and delirium; coma.
122
Q

Identify additional drugs that inhibit muscarinic receptor activity (3)

A
  • ·Diphenhydramine (H1 antagonist)
  • ·Tricyclic antidepressants
    • oProtriptyline
    • oAmitriptyline
  • ·Antipsychotic drugs
    • oChlorpromazine
    • oThioridazine
123
Q
  • Agents Acting at the Neuromuscular Junction (NMJ) and Autonomic Ganglia (nicotinic receptor targeting drugs)
  • Clinical use of NMJ blocking agent (2)
  • MoA of NMJ blockers
    *
A
  • ·Nicotinic receptors mediate neurotransmission at the NMJ
  • ·ACh is the neurotransmitter at the NMJ.
  • ·ACh triggers depolarization at the NMJ that in turn induces muscle contraction.

Clinical use of NMJ blockers

  • Induce muscle relaxation and diminish reflexes
  • tracheal intubation and surgery

MoA of NMJ blockers

  • Suppresses cholinergic transmission at the NMJ by blocking the effects of ACh at the nicotinic receptor
  • There are two types of neuromuscular blocking agents with two different mechanisms of action: non-depolarizing NMJ blockers, and a depolarizing NMJ blocker
124
Q
  • Identify Non-depolarizing NMJ blockers (6)
  • MoA
A

Non-depolarizing NMJ blocking drugs

  • •Atracurium
  • •Mivacurium
  • •Pancuronium
  • •Rocuronium
  • •Tubocurarine
  • •Vecuronium

Mechanism of action

  • competes with acetylcholine for binding to nicotinic receptors at the NMJ and this prevents depolarization and thus inhibiting muscle contraction
  • Therefore, reversed by increasing the acetylcholine concentration in the neuromuscular junction with acetylcholinesterase inhibitors (e.g., neostigmine).
125
Q

Adverse effects of Non-depolarizing NMJ blocking drugs

  • Tubocurarine
  • Pancuronium
  • atracurium, mivacurium, rocuronium, vecuronium
  • Prolonged apnea
  • CV collapse
A

Adverse effects:

  • •Tubocurarine – Induces histamine release, partial ganglionic block (fall in blood pressure, tachycardia)
  • •Pancuronium – partial ganglionic block (less than tubocurarine), vagolytic activity (blocks muscarinic receptors leading to tachycardia)
  • •atracurium, mivacurium, rocuronium, vecuronium are more selective for NMJ (cause very little ganglionic block)
  • •Prolonged apnea (all non-depolarizing blockers)
  • •Cardiovascular collapse (tubocurarine)
126
Q

Non-depolarizing NMJ blockers

  • Onset/duration of action (5)
  • Mode of elimination (5)
A

Onset/duration of action:

  • Tubocurarine: 6 min/85-100 min
  • Pancuronium: 1-3 min/85-100 min
  • Rocuronium: < 1 min/45-90 min (rapid acting)
  • Mivacurium: 1-3 min/15-21 min
  • Atracurium, vecuronium: 1-3 min/45-90 min

Mode of elimination:

  • Tubocurarine, pancuronium, vecuronium: renal and hepatic elimination
  • Rocuronium: renal elimination
  • Atracurium: elimination by plasma esterases
  • Mivacurium: hydrolysis by plasma cholinesterases
127
Q

Non-depolarizing NMJ blocking drugs

  • CNS effects
  • Drug interactions
    *
A
  • •CNS Effects
    • •No CNS effects (quaternary amines)
  • •Drug interactions:
    • •Anticholinesterases (reverses neuromuscular block)
    • •Halogenated hydrocarbon anesthetics (desflurane, sevoflurane, isoflurane, and halothane) will increase neuromuscular block.
    • •Ca2+ blockers will promote NMJ block effects by promoting muscle paralysis
    • •Aminoglycoside antibiotics will increase the neuromuscular block. (by inhibiting release of Ach?)
128
Q

Depolarizing neuromuscular blocking drug

  • Identify drug
  • MoA
    • How does this happen?
A
  • Drug
    • Succinylcholine
  • Mechanism of Action
    • Produces neuromuscular block by overstimulation of the nicotinic receptor, end plate is no longer able to respond to further stimulation.
    • This happens because succinylcholine is more resistant to acetylcholinesterase than acetylcholine leading to overstimulation.

**Depolarizing block at NMJ junction lead to paralysis?

Phase I block; Mebrane depolarize, result in initial discharge that produce transient fasiculations followed by flaccid paralysis

Phase II block; membrane repolarizes but receptor is desensitized to the effect of acetylocholine

129
Q

Describe MoA of succinylcholine

  • Phase I vs Phase II
A

•Phase I depolarization: prolonged depolarization (overstimulation), end plate can no longer respond to further stimulation and this leads to muscle paralysis.

•There is no antidote (just stop administering drug). Acetylcholinesterase inhibitor potentiates Block.

•Phase II depolarization: Repolarized, BUT blocked by succinylcholine (functioning like a non-depolarizing nicotinic receptor antagonist).

130
Q

Major Adverse effect of succinylcholine (3)

  • antidote?
A
  • Prolonged apnea
  • Muscle fasciculation
  • Malignant hyperthermia (more likely if succinylcholine is combined with halogenated hydrocarbon anesthetic (i.e., halothane, isoflurane, sevoflurane).
    • oUncontrolled Ca2+ release from sarcoplasmic reticulum is the trigger.
    • oClinical features: severe hyperthermia, muscle rigidity, tachycardia.
    • oLife threating (circulatory collapse).
    • oDantrolene is the antidote (blocks Ca2+ release from sarcoplasmic reticulum).
    • oGenetic component (mutations in the RYR1 gene increases risk).
131
Q

Identify medication

  • •Onset/duration of action:
    • 0.8-1.4 min/6-11 min (very rapid acting)
  • •Mode of elimination
    • •Hydrolysis by plasma cholinesterases
  • •CNS effects
    • •No CNS effects (quaternary amine)

***Identify drug interactions (2)

A

Succinylcholine

  • •Drug interactions
    • •Anticholinesterases enhance (prolong) succinylcholine-induced neuromuscular block.
    • •Halogenated hydrocarbon anesthetic (i.e., halothane, isoflurane, sevoflurane) are more likely to cause malignant hyperthermia when combined with succinylcholine.
132
Q

Drugs acting at Autonomic Ganglia (nicotinic receptor binding drugs) - (3)

A

Drugs:

  • oHexamethonium
  • oTrimethaphan
  • omecamylamine
133
Q

Identify Usual Predominant tone of ANS at various effector sites, and consequences of Autonomic Ganglionic Block

  • Arterioles
  • Veins
  • Heart
  • Iris
  • Ciliary muscle
  • GI tract
  • Urinary bladder
  • Salivary glands
  • sweat glands
  • Genital tract
A
134
Q

Identify drugs based on MoA

•Mechanism of action: (relatively specific)

  • oNicotinic receptor antagonists
  • oPrevent the effects of ACh by blocking its binding to nicotinic receptors at autonomic ganglia.
  • oNon-depolarizing block of nicotinic receptor signaling.

**Identify clinical use, effects and toxicity (7)

A

Ganglionic blocking drugs

•Clinical uses:

  • oNot used much. Severe toxicity (see below). Better agents are available.
  • oIntraoperative hypertension (reducing arterial pressure to control bleeding during various types of surgery
  • oHypertensive crisis

•Effects

  • •See table above showing the effects of ganglionic block

•Toxicity:

  • •Visual disturbance
  • •Dry mouth
  • •Urinary hesitancy
  • •Constipation
  • •Syncope
  • •Marked hypotension
  • •Paralytic ileus
135
Q

Identify medication based on MoA and actions

NICOTINE

A
  • Mechanism of action: Nicotine acts as an agonist at the nicotinic-cholinergic receptors in the autonomic ganglia, adrenal medulla, neuromuscular junctions, and brain
  • Pharmacological actions–Complex and often unpredictable changes after administration of nicotine; due to its actions on a variety of neuroeffector and chemosensitive sites and the fact that nicotine can stimulate and desensitize receptors
136
Q

Identify medication

  • Ultimate response of any one system is summatin of stimulatory and inhibitory effects
    • •The heart as an example.
  • increased heart rate–excitation of sympathetic cardiac ganglia and the paralysis of parasympathetic cardiac ganglia.
  • Or decreased heart rate–paralysis of sympathetic cardiac ganglia, stimulation of parasympathetic cardiac ganglia
  • Additional effects of the drug sites that influence heart rate; chemoreceptors of the carotid and aortic bodies (afferent reflex arcs)

Identify other effects at; ganglion cells, adrenal medulla, NMJ, CNS

A

NICOTINE

  • •Ganglion cells–stimulation with low doses, yet depolarizing block at higher doses.
  • •Adrenal medulla–biphasic action on the adrenal medulla; low doses evoke the discharge of catecholamines; larger doses cause depolarization block of nicotinic receptor.
  • •NMJ–similar to those on ganglia; stimulation phase (rapid and low dose) that is followed by depolarization block and then paralysis.
  • •CNS: Nicotine effects in CNS are in part attributed to stimulated release of neurotransmitters including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and others that mediate pleasure, arousal, mood, appetite, and other desirable psychological states.

•Low dose–stimulatory effect in the CNS

•High dose–tremors leading to convulsions at toxic doses
Suppression of respiratory controls in medulla oblongata (respiratory failure), Vomiting (emetic chemoreceptor trigger zone)

•primary sites of action in the CNS are prejunctional releasing other transmitters

137
Q

Identify drug based on physiologic effects

  • •CV system:
    • •peripheral vasoconstriction, tachycardia, and elevated blood pressure
  • •GI tract:
    • •Combined activation of parasympathetic ganglia and cholinergic nerve endings; increased tone and motor activity of the bowel
  • •Exocrine glands:
    • •Initial stimulation of salivary and bronchial secretions; followed by inhibition

***Identify absorption and toxicity

A

NICOTINE

•Absorption:

  • Inhalation (respiratory tract), Buccal membranes, skin (transdermal patch), severe poisoning has resulted from percutaneous absorption

•Toxicity

  • A regular cigarette may contain 13 to 30 mg of nicotine
  • Although an oral lethal dose has not been established, an estimated 40 to 60 mg of nicotine may be lethal
138
Q

Fungal Meningoencephalitis

  • seen in what type of patients
  • causative agents (4); which is important in HIVAID pts
  • causative agents in endemic areas (3)
  • 3 patterns of infection
A

A. Seen most often in immunocompromised patients
B. Causative agents

    1. Cryptococcus neoformans – important in HIV/AIDS pts
    1. Candida albicans
    1. Mucor sp.
    1. Aspergillus fumigates

In endemic areas:

    1. Histoplasma capsulatum
    1. Blastomyces dermatitidis
    1. Coccidiodes immitis

C. Three patterns of infection

    1. Vasculitis – direct invasion of vessel walls by fungus
    1. Chronic meningitis
    1. Parenchymal invasion – see granulomas and abscesses
139
Q

Other infectious diseases of the CNS

Protozoa (2)

Prion disease (2)

A

Protozoa

  1. CNS toxoplasmosis
  2. Amebas - rare causes

Prion disease

  1. Creutzfeldt-Jakob disease
  2. Variant Creutzfeldt-Jacob disease (vCJD)
140
Q

Protozoa - CNS toxoplasmosis

  • organism
  • morphology; cause what?
  • clinical?

Protozoa - Congenital toxoplasmosis

  • how it occurs? (TORCH or no)
  • causes? complications?
A

A. Protozoa (pp. 1279-80)
1. CNS toxoplasmosis

  • a. Toxoplasmosis gondii, intracellular protozoa
  • b. Common cause of neurologic disease in HIV/AIDS pts

1) Morphology

  • a) Brain abscesses
    • i. Especially in cerebral cortex
    • ii. Central foci of necrosis with petechiae
    • iii. Surrounded by acute and chronic inflammation, macrophages, vascular proliferation tachyzoites and bradyzoites

2) Clinical

  • a) Fever
  • b) Symptoms of acute cerebral dysfunction
  • c) CT-scan: Ring-enhancing mass lesion (often multiple)
  • d) Rx: anti-toxoplasma agents are effective

c. Congenital Toxoplasmosis

  • 1) Occurs when a pregnant woman becomes infected
  • 2) Risk of transplacental transmission increases with gestational age at which the mother becomes infected
  • 3) Infection causes calcification and ventricular dilation
  • 4) Also infects fetal retina causing retinochoroiditis
    • a) < 10% have visual impairment
  • 5) 5% have serious neurologic complications
    • a) Microcephaly
    • b) Hydrocephalus
    • c) Death
141
Q

Identify

  1. Most common human prion disease (~1:1,000,000)
  2. Primarily sporadic (>85% of cases) – Peak incidence in seventh decade (age 60s)
  3. Familial forms (10-15%) – Peak incidence younger than sporadic cases
  4. Rare iatrogenic cases (<1%)
  5. Clinical
  • a. Progressive mental deterioration (dementia, behavior changes, deficits in higher cortical functions)
  • b. Myoclonus (involuntary muscle twitching), ataxia
  • c. Progression to death within one year of symptom onset
  1. Morphology
  • a. Neuronal loss
  • b. Reactive gliosis
  • c. Spongioform change in neurons and glia of cerebral white matter
  • d. No inflammatory cell infiltration
A

Creutzfeldt-Jakob Disease

Clinical

a. Progressive mental deterioration (dementia, behavior changes, deficits in higher cortical functions)
b. Myoclonus (involuntary muscle twitching), ataxia
c. Progression to death within one year of symptom onset

Morphology

  • First you see GLIOSIS then neuronal loss
  • Spongiform changes
  • No inflammatory cell infiltration
142
Q

Protozoa - Amebas

**Idnetify 2 conditions

A
  1. Amebas – rare causes
  • a. Naegleria fowleri
    • 1) Rapidly fatal encephalitis
    • 2) Transmitted by swimming in freshwater lakes
  • b. Acanthamoeba – chronic granulomatous meningitis

**Through cribiform plate

143
Q

Identfiy 5 types of the following

  1. Long incubation period
  2. Associated with abnormal forms of a specific normal cellular protein (PrP), infectious and transmissible
  3. Change in protein may be spontaneous or heritable
  4. Altered PrP facilitates conversion of normal PrP
  5. Characterized by spongiform changes (intracellular vacuoles in neurons and glia)
A

Human Prion diseases

a. Kuru
b. Creutzfeldt-Jakob disease (CJD)
c. Variant Creutzfeldt-Jakob disease (vCJD)
d. Gerstmann-Straussler-Scheinker syndrome (GSS)
e. Fatal familial insomnia

144
Q

Identify condition

    1. Younger age (second to fourth decades)
    1. Linked to bovine spongiform encephalopathy (mad cow disease)
    1. More psychiatric symptoms (depression, anxiety, apathy) than CJD
    1. Morphology – amyloid plaques surrounded by spongiform changes
    1. Progression is slower, average time from symptom onset to death is 14 months
A

Variant Creutzfeldt-Jacob Disease (vCJD)

145
Q

Identify disease

A. Fifth leading cause of death in the USA
B. Most prevalent neurologic disorder
C. Categories

    1. Thrombosis
    1. Embolism
    1. Hemorrhage

D. Processes

    1. Hypoxia, ischemia, and infarction
    1. Hemorrhage
    1. Hypertensive cerebrovascular disease combines aspects of both
A

Cerebrovascular disease

146
Q

Pathophysiology of hypoxia, ischemia and infarction

  • what does brain need constant supply of (2)
  • 2 mechanism of decreased oxgen
  • what does survival of ischemic brain tissue depend on (3)
  • what is the region btw necrosis and normal brain called?
A
    1. Brain needs a constant supply of glucose and oxygen
    1. Mechanisms of decreased oxygen
      * a. “Functional” hypoxia
      • 1) Low inspired partial pressure of oxygen
      • 2) Impaired oxygen-carrying capacity
      • 3) Inhibition of oxygen use by tissue
        * b. Ischemia – transient or permanent
      • 1) Reduction in perfusion pressure, e.g. hypotension OR
      • 2) Secondary to small or large vessel obstruction
    1. Survival of ischemic brain tissue depends on
      * a. Availability of collateral circulation
      * b. Duration of ischemia
      * c. Magnitude and rapidity of the reduction of flow
  • 4. Penumbra – region between necrosis and normal brain that is at-risk tissue
147
Q

Global cerebral ischemia

  • due to what 3 things
  • outcome varies with?
  • Areas more sensitive to ischemia or hypoglycemia (3). 3 sets of neurons first affected
A
  • *Global cerebral ischemia** (hypotension, hypoperfusion, and low-flow states)
    1. General

a. Outcome varies with the severity of the insult
b. CNS cells show selective vulnerability

  • 1) Neurons are most sensitive and have the greatest variability
  • a) Areas more sensitive to ischemia or hypoglycemia
    • i) Large pyramidal neurons – may get pseudolaminar necrosis of cerebral cortex (see below)
    • ii) Hippocampus – Sommer sector is especially sensitive
    • iii) Purkinje cells of the cerebellum
  • 2) Glial cells also vulnerable

c. Severe global cerebral ischemia causes isoelectric – “flat” – electroencephalogram (EEG)

148
Q

Identify condition based on morphology

a. Brain is swollen, gyri widened, sulci narrowed
b. Poor demarcation between gray and white matter
c. Categories

  • 1) Early (12-24 hours) – red neurons
  • 2) Subacute (24 hours to 2 weeks) – necrosis (liquefactive) of tissue, influx of macrophages, reactive gliosis
  • 3) Repair (after 2 weeks) – removal of necrotic tissue; loss of normal CNS structure, and gliosis

d. UNEVEN destruction of the neocortex (pseudolaminar necrosis)
e. Border zone infarcts (watershed)

  • 1) Wedge-shaped
  • 2) Lie at the most distal fields of arterial irrigation
  • 3) Between anterior and middle cerebral artery distribution is at the greatest risk
  • 4) Usually after hypotensive episode
A

Global Cerebral Ischemia

149
Q

Describe what? - (infarction from obstruction of local blood supply)

  • General
    • what determines symptoms
    • modifying factors affect what 3 things?
  • Pathophysiology
    • caused by what (2)
    • explain these 2 causes
A

Focal Cerebral Ischemia

  1. General
  • a. Area of brain affected determines if patient is asymptomatic, develops hemiplegia, a sensory deficit, blindness, aphasia or another deficit
  • b. Fatal or slow improvement
  • c. Modifying factors affect size, location, shape
    • 1) Collateral flow, e.g. circle of Willis – NONE for thalamus, basal ganglia, and deep white matter
  1. Pathophysiology
  • a. Caused by a thrombus or embolism
  • b. Thrombosis
    • 1) Atherosclerosis at carotid bifurcation or origin of middle cerebral artery or either end of basilar artery – frequently associated with hypertension and diabetes
    • 2) Arteritis; a) Infectious vasculitis is now seen in immunosuppression and opportunistic infection, e.g. toxoplasmosis
  • c. Embolism
  • 1) Wide range of origins
    • a) Cardiac mural thrombi due to
      • i) Myocardial infarct
      • ii) Valvular disease
      • iii) Atrial fibrillation
    • b) Atheromatous plaque in carotid arteries
    • c) Paradoxical embolus
    • d) Cardiac surgery
    • e) Tumor, fat, or air
  • 2) Middle cerebral artery is most affected
  • 3) Embolism most often lodges at a branch point or stenotic area
150
Q

what morphology do you see after focal cerebral ischemia

  • Non-hemorrhagiv infact vs
  • Hemorrhagic infact vs
  • Spinal cord infarct
A

Focal Cerebral ischemia - morphology

Morphology
a. NON-hemorrhagic infarct – most often associated with thrombosis

  • 1) Gross
    • a) First 6 hours: little to observe
    • b) 48 hrs: pale, soft and swollen; corticomedullary junction becomes indistinct due to cerebral edema
    • c) 2 to 10 days: boundary of infarct is more distinct (edema resolves)
    • d) 10 days to 3 weeks: liquefies, fluid-filled cavity
  • 2) Microscopic
    • a) 12 hours: red neurons
    • b) 48 hours: neutrophils & microglia appear
    • c) 2-3 weeks: microglia are the most prominent cells;gliosis begins
    • d) Several months: astrocyte enlargement recedes

b. Hemorrhagic infarction – most often associated with embolism

  • 1) Hemorrhage is presumed to be due to reperfusion of damaged vessels and tissues through collaterals or after dissolution of occlusion
  • 2) Morphology – same as for ischemic infarct plus: blood extravasation and resorption.
  • 3) If patient is taking an anticoagulant, he/she may get more extensive intra-cerebral hematoma/s
  • 4) Venous infarcts are often hemorrhagic
    • a) Occlusion of superior sagittal sinus or other sinuses or deep cerebral veins
    • b) Carcinoma, localized infection or other causes of a hypercoaguable state which predisposes to venous thrombosis

c. Spinal cord infarction

  • 1) Cause: hypoperfusion or feeding tributaries are interrupted
  • 2) Rarely by occlusion of anterior spinal artery by thrombosis or embolism
151
Q

Neurotransmitters

  • synthesis is controlled by? (3)
  • Sites of synthesis? (3)
  • Termination of neurotransmitter action
A

Synthesis is controlled by:

  •  Amount and activity of synthetic enzymes
  •  Availability of substrates
  •  Presence of catalytic cofactors

Sites of Synthesis

  •  Cell soma - neuropeptides
  •  Nerve terminal cytosol - acetylcholine, GABA, etc.
  •  Vesicle - norepinephrine

Termination of Neurotransmitter Action

  •  Diffusion - neuropeptides
  •  Enzymatic degradation - acetylcholine
  •  Active re-uptake : primary mechanism
    • o high-affinity uptake mechanisms for neurotransmitters; can be into neurons or glia: norepinephrine
  •  Non-specific uptake: GABA
152
Q

Identify major transmitters (examples) based on the following classes

  • Biogenic amines (5)
  • Amino acids (4)
  • Nucleotides/Nucleosides (2m)
  • Peptides (1 major)
A
  • Biogenic amines; Acetylcholine, Dopamine, Norepinephrine, Epinephrine, Histamine, Serotonin
  • Amino acids; GABA, Glutamate, Glycine, Aspartate
  • Nucleotides/Nucleosides; Adenosine, ATP
  • Peptides; Enkephalins
153
Q

Identify neurotransmitter receptors (2)

A

A. Direct gating or ionotropic receptors:
 receptor is part of an ion channel

  • o depolarize cells:
    •  AMPA (Na+), kainite (Na+) and NMDA (Ca2+ and Na+) classes of glutamate receptors; nicotinic ACh receptors (Na+ and Ca2+) and 5-HT3 receptors (Na+)
  • o hyperpolarize cells:
    •  GABAA (Cl-) and glycine (Cl-) receptors

B. Indirect gating (G-protein coupled receptors; GPCRs) or metabotropic receptors:
 receptor activates a GTP-binding protein which can either:

  • o directly interact with an ion channel
  • o activate a second messenger system (cAMP, diacylglycerol, inositol polyphosphates)

alpha- & beta-adrenergic receptors, 5-HT receptors (except 5-HT3), all known dopamine, muscarinic, ACh, histamine and neuropeptide receptors, GABAB receptors and glutamate.

154
Q
  • Identify specific neurotransmitters (8)
  • Identify neuropeptides (4)
A

Neurotransmitters

  • Catecolamines
  • Dopamine
  • Norepinephrine (NE)
  • Indoleamines; Serotonin (5-HT)
  • Cholinergic (Ach)
  • Amino acid Neurotransmitters (can be excitatory or inhibitory in nature)
    • Excitatory receptors; Ligand gated ion channels and metabotropic receptors
    • Inhibitory receptors; GABAa and GABAb
  • Histamine
  • Purines

Neuropeptides (3-100 amino acids)

  • Substance P
  • Opiod peptides
  • Leptin
  • Orexin
155
Q

Catecholamines

  • 2 examples
  • synthesis
  • NE neurons contain what??
  • Termination of catecholamine action (2)
A

Catecolamines: The catecholamines of most interest for CNS pharmacology are:

  •  Dopamine (DA)
  •  Norepinephrine (NE)

Synthesis:
A common synthetic pathway is seen for each of the transmitters:
 DA synthesis occurs in the nerve terminal
 NE in Synaptic vesicles
Only NE neurons contain Dopamine ß-hydroxylase

Termination of Catecholamine action:
 Monoamine oxidase (MAO-A, MAO-B)

  • o Outer membrane of mitochondria in neurons/glia
  • o MAO inhibitors used therapeutically-most inhibit both forms

 Catechol-O-methyltransferase (COMT)

  • o Soluble form prevalent in brain
  • o Membrane form has a higher affinity for catecholamines
  • o Found in both neurons and glia

 Reuptake (80%):

  • o separate pumps exist for norepinephrine and dopamine
156
Q

Dopamine

  • 3 dopaminergic traits
  • role of DA in disease
  • metabolites of DA
A

Three dopaminergic tracts:

  •  Mesocortical/Mesolimbic Pathway
    • o Behavior/Emotion
  •  Nigrostriatal Pathway
    • o Motor Function (75% of brain DA)
  •  Tuberoinfundibular Pathway
    • o Neuroendocrine function
157
Q

Identify neurotransmitter (receptors - 3, metabolites)

 Produced in nuclei of the pons and medulla

  • o Locus ceruleus produces ~50% brain NE neurons
    •  Innervates forebrain, brainstem and spinal cord
  • o Other nuclei are in the brainstem
    •  Predominately innervate brainstem and spinal cord

 Involved in:

  • o anxiety, cerebellar function, learning, memory, mood, sensory processing, sleep (dreaming), arousal
A

Norepinephrine (NE)

  • Receptors
    • alpha 1, alpha 2, beta receptors
  • Metabolites of NE
    • VMA; vanillymandelic acid
158
Q

Identify neurotransmitter

  • produced by several brain stem nuclei in rostral and caudal clusters.
    • o Rostral nuclei innervate most of the brain
    • o Caudal Nuclei Innervate cerebellum, brainstem and spinal cord

Involved in:

  •  appetite, pain processing, hallucinations, sleep, mood (through interactions in limbic areas), temperature regulation, sensory perception

*****Desrcibe effect of the NT on; schizophrenia, depression, suicide, impulsive behavior, aggression

**Syntheis, termination and metabolism

**Receptors (4)

A

Indoleamines; serotonin (5-HT)

159
Q

Identify neurotransmitter

 Nuceli in the basal forebrain and brainstem supply the cholinergic innervation of the brain
Involved in:
 Memory, Sensory Processing, Motor Coordination, Wakefulness

  • Effect on; myasthernia gravis, parkinsons, alzheimers
  • Synthesis, termination and metabolism
  • Receptors
A

Cholinergic (Ach)

160
Q

Amino Acid Neurotransmitters

  • Excitatory amino acid neurotransmitters
    • involved in?
  • Synthesis, deactivation and metabolism
  • Receptors
A

Excitatory amino acid neurotransmitters:
 Glutamate, Aspartate
 Glutamate is the major excitatory neurotransmitter found throughout the brain
Involved in:
 Regulation of neuronal function, LTP
Synthesis, deactivation and metabolism:
 Glutamine converted to glutamate in mitochondria and packaged
into vesicles
 Deactivated predominantly by astrocytic uptake, where it is converted to glutamine
 Glutamine can be shuttled back to neurons
Receptors:
Ligand gated ion channels
 AMPA, Na+, K+
 Kainate, Na+, K+
 NMDA, Na+, K+, Ca2+
Metabotropic
 mGluR I
o Gi activation
 mGluR II & III
o Gq activation

161
Q

Inhibitory Amino Acids:
Gamma aminobutyric acid (GABA) – major inhibitory amino acid

  •  Present in inhibitory interneurons and projection neurons throughout the brain.

Involved in ?

Disease with a role for GABA?

Synthesis, deactivation, metabolism

Receptors

A

GABA

162
Q

Identify neurotransmitter

 Synthesized in the tuberomamillary nucleus
 Projections throughout brain and spinal cord
Involved in:
Wakefulness, equilibrium

  • Receptors (3)
A

HISTAMINE

Receptors:
H1
 Gq activated
 Cortex, hippocampus, nucleus accumbens, thalamus
H2
 Gs activated
 Basal ganglia, hippocampus, amygdala, cortex
H3
 Gi/o activated
 Basal ganglia, hippocampus, cortex

163
Q

Identify neurotransmitter

Adenosine as an atypical transmitter
Involved in:
Mood, sleep, pain
Receptors:
 A1
o Gi/o activation
 A2A
o Gs activation
 A2B
o Gs activation
 A3
o Gi/o activation

A

PURINES

164
Q

identify

  1.  Synthesized in cell body
     Metabolized by peptidases
     Do not undergo reuptake, degraded by peptidases
     Cotransmitter function
     Inhibitory/Excitatory
  2.  Localized in neurons of the dorsal root ganglia
     “Sensory” neurotransmitter in peripheral nervous system
     Transmission of “pain” information; behavioral effects (depression,
    anxiety)
     Receptors: tachykinin receptors (NK1, NK2, NK3, etc)
    o All Gq activation
A
  1. Neuropeptides (3-100 amino acids)
  2. Substance P
165
Q

Identify types of Opiod peptides (3)

  1. o Leucine enkephalin, methionine enkephalin;
    o CNS interneurons
    o Location: Nerve plexuses of GI tract
    o Location (pain perception):
     Lamina I, II of spinal cord
    o Location (modulation of affective behavior):
     amygdala, hippocampus, locus ceruleus, cerebral cortex
    o Location (regulation of autonomic nervous system):
     medulla oblongata
  2. o Localized in arcuate nucleus of hypothalamus, nucleus tractus solitarius and in the anterior lobe of pituitary where it is coreleased with ACTH in response to stress
    o Localized in spinal cord
    o Localized in pancreatic islet cells
  3. o Dynorphin colocalizes with vasopressin in the hypothalamus and posterior lobe of the pituitary gland
    o Dynorphin present in laminae I and II of the spinal cord
A
  1. Enkephalins: (derived from proenkephalin)
  2. Endorphins: (derived from proopiomelanocortin)
  3. Dynorphins: (derived from prodynorphin)

Opioid receptors are very important targets for pain treatment and are also important in drugs of abuse

166
Q

Identify hormones

1.

 protein hormone with important effects in regulation of body weight, metabolism and reproductive function
 Receptors in Hypothalamus which controls feeding behaviour/hunger, body temperature and energy expenditure

  • ↑ Leptin → ↓ body weight
  • ↓ hunger/food consumption (inhibition of neuropeptide Y)
  • ↑ oxygen consumption

2.

  •  Stimulates appetite (hypothalamic receptors)
  •  Stimulates “drug-seeking” behavior
  •  Potential role in narcolepsy
A
  1. Leptin
  2. Orexin
167
Q

Define the following concepts in neuropharmacology

  • Receptor number modulation
  • Tolerance
  • Dependence
  • Drug abuse
  • Drug addiction
  • Withdrawal
A
168
Q

What is hypokinesia and what are hypokinesia movement disorders

A
  • Hypokinesia refers to decreased bodily movement and is typically associated with diseases of the basal ganglia.
  • The prototypical hypokinetic movement disorder is Parkinson’s Disease
    • There are a number of Parkinsonisms (diseases which have similar initial presentations to Parkinson ’s Disease but dramatically different clinical course and underlying pathology). These diseases include progressive supranuclear palsy (PSP), Multi-Systems Atrophy (MSA), and Corticobasalgangionic Degeneration (CBGD) which can be read about elsewhere but are outside the scope of this lecture.
169
Q

Define the pathophysiology of Parkinson’s Disease

A
  • Parkinson’s Disease (PD) is a neurodegenerative disorder in which neurons within the substantia nigra die prematurely.
  • ▪ Studies suggest that over 50% of the cells must die prior to the onset of evident symptoms.
  • ▪ In most patients, we do not know why it occurs and it is in these patients that we see neurodegeneration in the substantia nigra, as well as in some of the other pigmented nuclei, such as the locus coreuleus
  • • It is this group of patients that we refer to as idiopathic or primary Parkinson’s Disease
170
Q

Causes of parkinson

▪ There are some clear causes for Parkinson’s Disease (when a clear cause is identified we refer to these patients as having secondary Parkinson’s Disease). Below is a discussion about some of the main causes of secondary Parkinson’s

A

Disease.
• Structural lesions

  • o Obviously, structural pathology within the substantia nigra from stroke, tumor, cavitary infection etc. can cause Parkinson’s Disease. However, in practice, such causes are extremely rare.

• Infections

  • o In the 1920’s, an epidemic of encephalitis, called Von Economo’s encephalitis (or encephalitis lethargica) spread across the country. Patients would sometimes wake up from infectious coma with acute parkinsonism. Currently, there are still some forms of encephalitis that can cause parkinsonism (e.g. Japanese B encephalitis); fortunately these are quite rare.

• Toxins

  • o It has long been known that carbon monoxide, carbon disulfide, manganese, and L-BMAA toxicity (the false sago palm plant on Guam), can be associated with clinical parkinsonism.
  • o It wasn’t until some would-be users of designer drugs (stove-top drugs that resemble known drugs of abuse closely enough to simulate their psychotomimetic effects, but that differed structurally enough to them that they were considered misdemeanor crimes of possession rather than felonies) stumbled across MPTP, a mistaken byproduct of attempted meperidine (Demerol). MPTP was found to have unmistakable and immediate Parkinson’s Disease effect.
    o MPTP is selectively and highly toxic to neurons within the substania nigra. Humans who take it can develop severe, acute Parkinson’s Disease. This enabled researchers to create a toxic model of parkinsonism in animals.
    ▪ Now genetic models of Parkinson’s Disease in animals are of more practical value, but MPTP toxicity remains a useful research tool.

Prescription Medications

  • o Since the symptoms of Parkinsonism result from loss of nigrostrital dopamine neurons, it can be mimicked by drugs that impair dopamine neurotransmission.
  • o Most commonly, this is seen with neuroleptics, such as haloperidol or chlorpromazine (Thorazine), but it can also be seen with drugs that deplete dopamine, such as reserpine.
  • o Metaclopramide. (Reglan) is a drug for diabetic gastroparesis that has many features of neuroleptics. This frequently asked about by the USMLE as the cause of secondary parkinson’s disease**HINT-HINT.

• Trauma

  • o Parkinsonism can follow acute or chronic trauma. Muhammad Ali is a good example of this.
  • o It is felt that trauma induces parkinsonism by damaging the cells of the substantia nigra directly, or by causing shearing injuries to nigrostriatal connections.
  • o Acute trauma can also cause parkinsonism that may be in part reversible, this seems to be the result of acute edema that dissipates over 3-4 days. Remember that other structural lesions of the brain in the basal ganglia can cause a parkinsonian syndrome, but that such lesions (tumors, strokes, hemorrhages, aneurysms, etc) are quite rare.
171
Q

typical clinical features of parkinson’s disease

A

Features of Parkinson’s Disease can be best remembered using the pneumonic TRAP (Tremor, Rigidity, Akinesia, Postural Instability)
• Tremor

  • The tremor of Parkinson’s Disease is a rest tremor with a frequency of 3-5 Hz and you get the impression that, on exam, you can count along with it.
  • o Classically, Parkinson’s Tremor improves when the arm moves, so, if it is a rest tremor, it should improve with action to some degree
  • o The tremor is usually worse on one side early in the disease process

• Rigidity

  • o The rigidity seen in Parkinson’s Disease is typically noted in the arms, but can be noted in the legs, neck or trunk as well
  • o “Cogwheeling” (ratchet-like feeling) with extension and flexion at the elbow and wrist are common

• Akinesia-More often bradykinesia

  • o Slowness of movements
  • o Some patients can “freeze” (also known as being akinetic) with more advanced Parkinson’s Disease
    • ▪ Freezing is typically seen at times when there medication (Carbidopa-Levodopa-see below) wears off.

• Postural Instability

  • o Parkinson’s Disease results in multiple problem areas which disrupt balance. The above described rigidity and the slowness of movements play a large role in the cause of frequent falls.

• Other Signs Typically Observed in Parkinson’s Disease

  • o Gait impairment: slowness and difficulty rising from a chair, turning in tight quarters, taking small steps,
  • o Softening of voice
  • o Micrographia (small handwriting)
  • o Slowness in fine motor skills (buttoning buttons, stirring while cooking, flipping pancakes, tying shoes, etc.)

• Other Symptoms Observed in Parkinson’s Disease

  • o Constipation
  • o Dry skin (seborrhea)
  • o Dizziness upon standing (orthostasis)
  • o REM Sleep Behavior Disorder (act out dreams)
  • o Depression
  • o Hallucinations (late in disease)
172
Q

Understand the medications available to treat Parkinson’s Disease

Medications vs surgical tx

***Advantages and disadvantages of the main drug***

A

Carbidopa/Levodopa (Sinemet™)

  • o Gold standard treatment
  • o Acts by crossing the blood brain barrier and converting to dopamine by ALAA-decarboxylase
  • o Eventually all PD patients require it

MAO-B Inhibitors

  • o Selegiline, Rasagiline
  • o Act by selective inhibition of MAO-B enzyme involved in dopamine metabolism
  • o Is possible neuroprotective
  • o Drawbacks:
    • ▪ Tons of drug interactions
    • ▪ Very mild anti-Parkinson’s dug

• Dopamine Agonists

  • o Pramipexole and ropinirole
  • o Directly stimulate D2/D1 receptors
  • o Less efficacious than levodopa but more than MAO-BI and amantadine
  • o Also has indication in restless leg syndrome
  • o Drawback:
    • ▪ Pathologic gambling and impulsivity in general
    • ▪ Can cause sudden sleep attacks

• Amantadine

  • o Mechanism of action not known: NMDA blockade?
  • o Effective at reducing dyskinesia

• COMT Inhibitors

  • o Entacapone, Tolcapone
  • Inhibit COMT => slows dopamine breakdown => prolongs the half life of levodopa
  • o Used in advanced PD when patients are experiencing motor fluctuations
  • o Tolcapone has longer half-life but use limited by bimonthly LFT monitoring to monitor for hepatoxicity
  • o Always have to be given with levodopa

Surgical treatment

Deep Brain Stimulator (DBS)
o Which patients to consider for DBS

  • ▪ Advanced PD patients, who are not demented, having any of the following symptoms which cannot be adequately controlled with medications.
    • • Motor fluctuations;
    • Disabling dyskinesia or dystonia
    • • Medically refractory tremor
    • • Medication induced intolerable side effects
  • o Positive effects of DBS on Parkinson’s Disease Patients
    • ▪ Marked improvement in motor symptoms
    • ▪ Improvement in tremor by ~80%
    • ▪ Increases the ‘On’ time and ‘smoothes’ out motor fluctuations when using carbidopa/levodopa
    • ▪ Dyskinesias improve 60-80 %
    • ▪ Quality of life improvement ~ 50%
  • o Symptoms which fail to improve with DBS
    • ▪ Speech (may even worsen)
    • ▪ Cognition
    • ▪ Postural instability and gait (if unresponsive to levodopa)
    • ▪ Autonomic symptoms (constipation, orthostasis)
173
Q

Define the pathophysiology and typical clinical features of Lewy body dementia

A

▪ Lewy Body Disease results from the deposition of abnormal Tau proteins (Tau-opathy) throughout the subcortical white matter.
o Clinical Features

  • ▪ Motor
    • • Parkinsonian motor features preceding cognitive and psychiatric features (generally only a year before)
  • ▪ Psychiatric
    • • Fluctuations in cognitive function with varying levels of alertness and attention (eg, excessive daytime drowsiness despite adequate nighttime sleep or daytime sleep >2 hours, staring into space for long periods, episodes of disorganized speech)
    • • Visual hallucinations
      • o Well-formed and are typically people or animals. Initially they are insightful that these are not actually present

o Cognition
▪ Anterograde memory loss: May be less prominent (vs prominent early sign in Alzheimer disease)
▪ More prominent executive function deficits and visuospatial impairment

174
Q

Define the pathophysiology and typical clinical features of Normal pressure hydrocephalus

A

Pathophysiology
▪ CSF volume increase results in increased subarachnoid space volume. This disrupts normal blood flow as well as the positioning and function of some subcortical white matter structures:

  • • Sacral motor fibers that innervate the legs and the bladder, thus explaining the abnormal gait and incontinence.
  • • Brainstem structures (ie, pedunculopontine nucleus) could also be responsible for gait dysfunction, particularly the freezing of gait that has been well
  • • Periventricular limbic system resulting in the dementia component

o Clinical Features
▪ Motor

  • • Abnormal gait: Earliest feature and most responsive to treatment; bradykinetic, broad-based, magnetic, and shuffling gait

▪ Cognitive

  • • Dementia: Prominent memory loss and bradyphrenia; forgetfulness, decreased attention, inertia

▪ Other

  • • Urinary incontinence: Urinary frequency, urgency, or frank incontinence
175
Q

Understand the role of CSF shunting in the diagnosis and treatment of normal pressure hydrocephalus

A
  • CSF volume increase results in increased subarachnoid space volume. This disrupts normal blood flow as well as the positioning and function of some subcortical white matter structures:
  • Decreased CSF absorption
176
Q

Describe Wilson’s disease

  • inheritance trait
  • clinical findings
  • Work up
  • Treatment
A

o Autosomal Recessive mutation of ATP7B- hepatic copper accumulation  leak from damaged hepatocytes  deposits in tissues (e.g. basal ganglia and cornea).

  • ▪ The excess copper causes injury by binding to sulfhydryl groups of cellular proteins.

o Clinical findings include:

  • ▪ Hepatic (acute liver failure, chronic hepatitis, cirrhosis)
  • ▪ Neurological (parkinsonism, gait disturbance, dysarthria) psychiatric (depression, personality changes).
  • ▪ Ophthalmic (Keiser Fleisher Rings)

o Work-up

  • ▪ Ceruloplasmin (decreased)
  • ▪ Elevated transaminases
  • ▪ Urinary copper excretion (increased)

o Treatment:

  • ▪ Chelators (D-penicillamine, trientine) or Zinc (interferes with copper absorption).
  • • D-penicillamine is the first line agent and chelates copper by containing a free sulfhydryl group.
177
Q

Define the pathophysiology and typical clinical features of Huntington disease

A

Huntington’s Disease (HD) is a neurodegenerative disorder in which neurons within the caudate nucleus and putamen undergo rather striking degeneration compared to other cerebral structures.

o Clinical Features
▪ Motor

  • • HD is the prime example of the hyperkinetic movement disorder Chorea.
    • o Chorea is derived from the Greek word meaning dance and appears as writhing type movements.
  • • Initially, mild chorea may pass for fidgetiness. Severe chorea may appear as uncontrollable flailing of the extremities (ie, ballismus), which interferes with function.
  • • As the disease progresses the patient can appear somewhat parkinsonian, with rigidity, bradykinesia, and postural instability replace the irregular choreaform hyperkinesis.
  • • In advanced disease, patients develop an akinetic-rigid syndrome, with minimal or no chorea.

▪ Cognition

  • • The dementia syndrome associated with HD includes early onset behavioral changes, such as irritability, untidiness, and loss of interest.
  • • Slowing of cognition, impairment of intellectual function, and memory disturbances are seen later.

▪ Psychiatric

  • • Depression is more prevalent, with a small percentage of patients experiencing episodic bouts of mania characteristic of bipolar disorder.
  • • Patients with HD also can develop psychosis, obsessive-compulsive symptoms, sexual and sleep disorders, and changes in personality.
  • • Patients with HD and persons at risk for HD may have an increased rate of suicide.
178
Q

Define the genetic basis for Huntington’s Disease and understand the term and implications of “genetic anticipation

A
  • ▪ Huntington’s Disease (HD) is a neurodegenerative disorder in which neurons within the caudate nucleus and putamen undergo rather striking degeneration compared to other cerebral structures.
  • ▪ Estimates of the prevalence of HD in the United States range from 4.1-8.4 per 100,000 people
  • ▪ The genetic basis of HD is the expansion of a cysteine-adenosine-guanine (CAG) repeat encoding a polyglutamine tract in the N -terminus of the protein product called huntingtin. This is a problem localized to chromosome 4.
  • ▪ This is a disease of genetic anticipation- each subsequent generation develops more CAG repeats which results in earlier and more aggressive disease.

• **USMLE and others like for you to know its due to CAG trinucleotide repeat on chromosome 4**

179
Q

Treatment options of Huntington’s disease (3)

  • Profound dopamine depleting agent
  • First line therapy for depression
  • treat psychiatric symptoms of hallucination and delusions
A

▪ Tetrabenazine (Xenaxine™)

  • • Profound dopamine depleting agent (actually prevents a monoamine transporter protein) which can decrease choreaform movements
  • • Very high association with inciting depression. Patients and family must be warned about symptoms of depression

▪ Selective serotonin reuptake inhibitors (SSRIs)

  • • Should be considered as first-line therapy for depression

▪ Antipsychotics

  • • Treats the psychiatric symptoms of hallucination and delusions which can occur in HD
180
Q

Some viruses that cause meningitis vs viruses that cause encephalitis

A

Viruses that can cause meningitis include: Herpes simplex virus (DNA virus)

Mumps virus (RNA virus)

Lymphocytic choriomeningitis virus (RNA virus)

Poliovirus, Coxsackievirus and Echovirus and Enteroviruses(newly identified) (RNA viruses, Enteroviruses)

Encephalitis viruses (RNA viruses, eg. Toga and Flaviviruses)

HIV (RNA-Retrovirus)

Numerous viruses can also cause encephalitis.

Herpes simplex virus and Varicella zoster virus (DNA viruses) Human Herpes virus 6 (DNA virus)

Cytomegalovirus (DNA virus) Poliovirus (RNA virus)

Enteroviruses,Coxsackie and ECHO (RNA virus)

Mumps virus (RNA virus)

Measles virus (rubeola- RNA virus) Nipah virus (RNA virus)

Rabies virus (RNA virus) Encephalitis viruses (RNA viruses) JC virus (papovavirus- DNA virus )

Zika virus (RNA virus)

Adenovirus (DNA virus)

181
Q

Know the pathogenesis of picornavirus infections

The family Picornaviridae is comprised of viruses isolated from animals and humans. The group includes:

  • 1)the human enteroviruses (polioviruses, coxsackieviruses groups A and B, echoviruses, hepatitis A virus)(Hepatitis viruses are covered in separate section) and
    • Enterovirus (acid stable); cause respiratory and intestinal Disease; Also Cause neonatal disease, carditis, vesicular disease (Hand, Foot and Mouth,conjunctivitis and congenital disease
  • 2) rhinoviruses (see respiratory system virus lectures). The virus causing Foot and Mouth Disease (FMDV) is a major threat to the cattle industry, but does not infect man. The most widely known viruses in this group are the polioviruses, of which there are 3 serotypes (1,2,3). Man is the only reseivoir
A

Picornaviridae Genera: Enterovirus, Rhinovirus

182
Q

role of various picornaviruses in causing infections of the CNS.

A

Possible infections by poliovirus

a. Inapparent infections- vast majority of cases in young individual (90%)
b. Abortive poliomyelitis - fever, malaise, headache, vomiting, sore throat- About 5%
c. Nonparalytic CNS disease (“aseptic meningitis”) - stiffness and pain in neck and back;crossesfenestrated endothelial cells at the choroid plexus,1-2%
d. Paralytic –spinal, bulbar (back of neck, pons & medulla) - flaccid paralysis - changes in voluntary muscle most likely to occur in teenagers and young adults, 0.1-2%

Paralysis induced by poliovirus infection

Spectrum of levels of flaccid paralysis

  • Asymmetric paralysis with no sensory loss
  • Localized flaccid paralysis
  • Multiple Sites (arms and legs affected)

3 outcomes of recovery from flaccid paralysis

  • Full recovery
  • Residual paralysis
  • Death (bulbar poliomyelitis)
183
Q

Know the major structural features of the virion and characteristics of its replication cycle.

A

A.Single stranded, non segmented RNA

B.+ polarity genome (can act as messenger RNA)

Genome = AUGGC; mRNA = AUGGC

Genome can “transfect” cells; naked genomic RNA is introduced into a cell and infection is initiated

C. RNA has poly A at 3’ end and VPg at 5’ end (VPg is not a cap structure)

D. Capsid has 4 structural proteins; VP1, VP2, VP3, VP4.

Icosahedral capsid - no envelope

F. Capsid structure is stable to acid (enteroviruses) and the environment, rhinoviruses not acid stable (rhinoviruses are not enterovirus)

184
Q

Factors that potentiate impact of poliovirus and enterovirus disease outcome (6)

A
  • Viral serotype (1,2,3)
  • Quantity of live virus causing initial infection
  • Tissue specificity of viral serotype
  • Portal of entry (fecal-oral route for enteroviruses)
  • Age, gender, and health of individual(immune status)
    • AGE Factor-First exposure to poliovirus at a young age ——-> less paralysis;
    • first exposure during adolescence and adulthood –> paralysis more likely; delayed exposure leads to more severe disease
    • early exposure to poliovirus in developing countries and low socioeconomic conditions; yield inapparent or abortive infections
  • Pregnancy
185
Q

Know the status of the two types of poliovirus vaccines and the advantages and disadvantages of each. Know the proper specimens for virus isolation at each stage of infection and laboratory procedures used for diagnosis.

A

Vaccine induced immunity, two primary types of vaccines –killed

(Salk= IPV)) vs. live (Sabin= oral) vaccines

Salk (Killed) induces serum AB vs. Sabin (live attenuated)induces both secretary Ab and serum AB

vaccine - associated” paralysis may be linked to the Sabin live vaccine, absolute need to maintain immunization, once begun

186
Q

Learn about the efforts to eradicate poliovirus from world populations.

A
  • The World Health Assembly has a goal to eradicate poliovirus infection from world populations during the next decade and progress is being made. The Western Hemisphere has been free of W+ (natural infection) since 1994. The Western Pacific region was certified in
  • 2000 and the European Region (Europe and Russia) was certified wild type polio free in 2002. Three remaining major reservoirs of natural
  • polio included: 1) Pakistan, 2) Afghanistan, and 3) Nigeria. *** Northern India (eradicated by 2014)
  • Poliovirus stocks (W+= Wildtype) are in many research laboratories around the world. To ascertain the location of lab. stocks of poliovirus, inventories are being conducted and a database is being established. Stocks not being used for research and merely being held in the freezer are destroyed. It is therefore anticipated that natural poliovirus infections will be eliminated worldwide and all efforts to contain laboratory virus must be made.
  • In addition, Vaccine derived poliovirus (avirulentà neurovirulent mutation) is being tracked and a genome sequence database is being developed to determine how mutations occur and affect neurovirulence.
  • For global eradication of polio to occur, WHO has instituted National Immunization Days where susceptible children in a whole country will be vaccinated by door to door canvassing.
  • A network of sophisticated diagnostic laboratories has been developed to monitor natural and vaccine associated prevalence of poliovirus. Even after natural poliovirus has been eradicated it could possibly be re-introduced into the population by: 1) accidental release from research and diagnostic laboratories and
  • 2) mutation of OPV (Sabin).
  • Vaccine recommendations:Previouslythe oral poliovirus vaccine was recommended as a series of three primary doses. The concern then and now is that vaccine (live attenuated) viruses would mutate to neurovirulence, excreted into the environment, and cause paralytic disease in susceptible individuals. Over the last several years the recommendations for poliovaccine administration have changed significantly inUSA.
  • In the UStheinactivated poliovirus vaccine (IPV) is now recommended. If a live poliovaccine is used, it is a concern that a pathogenic form (mutant, neurovirulent form) of live vaccine virus will be released into the environment via fecal contamination. In other parts of world where poliovirus has been endemic, 3 doses of oral poliovirus vaccine (live) is still recommended.
  • Per January-December 2017 recommendations, IPV should be administered for all children via a 4 shot series. Immunization should be administered at 2 months, 4 months, between 6 and 18 months and between 4 and 6 years.
187
Q

Lab diagnosis of poliovirus (5)

A

Lab diagnosis (paralytic disease with CNS involvement)

  • a. Increased leukocytes in CSF 10-200/ mm3
    • Lacks neutrophils
  • b. Elevated protein in CSF 40-50 mg/dl(10-45 normal)
  • c. Glucose normal 40-70mg/dL
  • d. serological testing of types 1, 2, 3
  • e.Virus isolation:rectal or pharyngeal swabs;foundin throat and stools before clinical illness poliovirus not usually found in CSF in paralytic disease (unlike coxsackie and echovirus induced meningitis and encephalitis where virus can be isolated from CSF)

Antibody and antigen test available to diagnose serotypes including immunofluorescence and ELISA

RT PCR (Reverse Transcriptase= RT) is being used for routine testing of a number of different enteroviruses

188
Q

Know that coxsackieviruses have become more prominent as an etiologic agents of acute and chronic heart disease in addition to causing other syndromes.

2 groups of coxsackievirus

lab diagnosis

A

Coxsackieviruses - diverse disseminated infections - summer, fall

Group A (23 types) -

1)vesicular pharyngitis or herpangina; tonsils pharynx, anorexia,dysphagia (posterior enanthem);

Remember for HSV gingivostomatitis, lesions are seen throughout the oral cavity

2) summer grippe, febrile illness;
3) aseptic meningitis -stiff neck, back; nausea, headache, abdominal pain, fever virus in CNS; petechiae or rash may accompany meningitis, recovery uneventful except if meningoencephalitis develops

NOTE: Non-polio enterovirues are leading infectious cause of aseptic meningitis in US; > 80% of cases;age is major determinant of severity, older patients= more severe disease

4) colds, one of the many cold viruses
5) Hand, Foot & Mouth (HFM) disease lesion

and exanthems) -no crusting of exanthem,

  • Enterovirus 71 HFM Disease plus high frequency of neurological complication; Currently HFM Disease cases are being reported in colleges in various locations throughout the United States
    6) CA24 (variant) and enterovirus 70 cause acute hemorrhagic conjunctivitis in tropics

Group B (6 types) –

1) summer grippe;
2) epidemic myalgia, severe pain in chest, (pleurodynia or devils grippe) fever;
3) aseptic meningitis (virus in CNS);
4) neonatal disease, primary Myocardial or pericardial disease;cyanosis (reduced Hemoglobin in skin, blue
skin) tachycardia>100 beats/min; dyspnea, difficulty breathing;
5) colds;
6) diabetes,
7) macular -papular rash

Lab diagnosis

a. Isolation of virus from throat (1st), feces (2nd) or CSF in encephalitis
b. If (Immunofluorescence)
c. RT PCR
d. Neutralization ab (found early in infection)

189
Q

Echoviruses

A

ECHOviruses - enteric cytopathogenic human orphan (over 30 types)

- summer aseptic meningitis -type 11(virus in CSF), RT PCR used for diagnosis of type 11 Echovirus meningitis

  • summer epidemics of febrile illness with rash, esp. in young, eg. Boston Exanthem, maculopapular rash
  • outbreaks of non-bacterial diarrheal disease in infants, ECHO 11,14, 18
  • not pathogenic for mice (unlike Coxsackie)
  • recovered from throat and stools
190
Q

Know that rhinoviruses (acid labile) are the major cause of the common cold and that there are over 100 immunotypes. Discuss the feasability of a cold vaccine.

A
191
Q

Learn differences between conventional and unconventional slow viruses

A

I. Slow viruses

  • The term “slow infection” was first used in 1954 by Sigurdsson to describe chronic diseases which developed insidiously, following a prolonged, predictable course. The disease usually ends in death.
  • “Slow” now applied to long incubation diseases and the slow agents that produce them. The terms denotes a virus-host relationship. Incubation time, months to years

A. Conventional (viral) agents - are classic viruses

    1. Replicate in vitro, producing CPE
    1. Antigenic viral proteins
    1. Evoke an inflammatory reaction of CNS; examples (SSPE measles, visna retrovirus)

B. Unconventional agents

    1. Do not produce CPE in vitro
    1. Virus particles cannot be demonstrated by EM, can detect rod shaped particles which may or may not correspond to infectious entity
    1. No inflammatory response in CNS
    1. Do not evoke Ab response during disease development
    1. Do not cause interferon to be produced
    1. Can be propagated in animals
192
Q

Learn about persistent infections and the role of ts mutants and defective interfering particles.

A
193
Q

How does Normal PrP (Prion) serve role in neuron function

A
  • PrPc is anchored to phosphatidylinositol glycan that is embedded in the cell surface membrane
  • PrPc is encoded by Pmp gene and is expressed at high levels in all adults, expression regulated during development
  • May control ion flow across membranes in neurons
  • Normal PrPc has a N-terminal polypeptide which is flexible and a C-terminal polypeptide which is ridged
  • N-terminal polypeptide has toxic properties for neurons but this is held in check by the presence of the C-terminal polypeptide
  • Mab directed to C-terminal polypeptide causes the N-terminal polypeptide to express its toxic properties towards neurons
194
Q

Diseases caused by unconventional agents or prion designed PrP sc

A

II. Diseases caused by unconventional agents or Prion

(Small Proteinaceous Infectious Particle) designated PrPsc

A. Scrapie - disease of sheep marked by tremors, ataxia, etc., no demyelination, no pleocytosis, no febrile reaction, no meningeal signs

  • Sheep scrape off wool from skin
  • Disease causes spongiform changes in gray matter - destruction of neurons
  • Scrapie as well as other similar human and animal CNS degenerative diseases may be genetic and/or infectious in origin

Is scrapie a virus? It has beensuggested (historically)that the scrapie agent is:

  • a. A self-replicating membrane polysaccharide, unlikely
  • b. A nucleic acid covered by a polysaccharide
  • c. plant viroid-like - small circular ssRNA - membrane associated, Group I introns (self splicing intron)
  • d. protein (PRION) - aberrant protein (PrPsc) closely related to normal cell protein(PrPc);
    • PrPsc associates to form Scrapie Associated Fibrils (SAF) - found in Brain, spleen- none in normal tissue, may form rods which resemble amyloid ultra-structures
    • PrPc corresponds to protease sensitive protein with a mw of 33 to 35 kd,
    • PrPsc has a core polypeptide, 27-30 kd, which is protease resistant
195
Q

Review evidence that (3) are caused or initiated by viruses (conventional).

A

multiple sclerosis, subacute sclerosing panencephalitis, and visna

196
Q

Discuss the lack of evidence for the viral etiology of what conditions (4)

A

Kuru, Creutzfeldt Jakob disease, and Gerstmann-Straussler Scheinker (GSS) Syndrome, fatal familial insomnia (FFI).

197
Q

Scrapie; A model prion system

Characteristics of scrapie agent (PrPsc )and other prion disease agents (7)

A
    1. Can withstand heating to 80o C
    1. Not inactivated by formalin - brain tissue in formalin is still infectious after 7 years - threat to pathologists
    1. Resistant to U.V. irradiation
    1. Resistant to ionizing irradiation
    1. Transmissible in animals
    1. Inactivate by chlorox (sodium hypochlorite)
    1. No immunity - except for Ab to neurofilaments
198
Q

Pathogenicity of scrapie

A
  • Both normal and scrapie infected cells haveDNA (gene) which codes for PrPc (cellular prion protein), Pmp gene
  • PrPc coding region is within one exonand not varied via splicing process,
  • PrPc mRNA is constitutively expressed in brains of adult animals, but regulated during development
  • Alterations of PrPc in scrapie cells to form PrPsc is a protracted, posttranslational event, both PrPc and PrPsc are glycosylated in the form asparagines linked oligosaccharides in the Golgi via sialic acid addition;
  • PrPc is transported to plasma membrane and anchored there via phosphatidylinositol glycan
  • PrPsc accumulates in cells and is deposited in cytoplasmic vesicles (vacuolation of neurons) or it can be released from the cell surface
  • Several possible explanations of how an aberrant prion protein (PrPsc ) can cause disease and also be transmissible (infectious disease aspect)
    • The PrPc (normal prion) gene is mutated to produce a protein product which folds at the tertiary level in an abnormal configuration PrPsc.
  • This abnormal protein in some way causes CNS degeneration. A small number of PrPsc proteins can act like infectious agents by interacting with normal PrPc to form a dimer (or other complexes).
  • PrPsc causes normal PrPc to fold in the pathogenic configuration thus amplifying number of the aberrantly folded proteins and increasing the number of pathogenic units.
199
Q

Animal disease caused by unconventional agents

A
  • Mad cow disease (bovine spongiform encephalopathy, BSE) in United Kingdom. Cattle feed in UK supplement with ground up meat from scrapie infected sheep.
  • Cows exhibit symptoms of scrapie
    • Primary question: Can humans acquire the infection from eating contaminated beef?
  • Several cats have exhibited symptoms possibly from infected cat food. What about zoo animals? (grind cat food and give to zoo animals)
200
Q

Describe human encephalopathies

familial vs infectious transmission

A

1) Genetically Based Disease (familial transmission) and 2)Infectious transmission

In the case of humans, familial origins of prion disease results from mutations in the normal PrP gene, which is located on short arm of human chromosome 20 and in a homologous position of chromosome 2 in mice

  • a)for CJD a 144 bp insert found at codon 53 plus other mutations in the PrP gene have been noted, for GSS point mutation at codon 102 has been found protein product of mutated gene may become transmissible from person to person; mutated protein product equivalent to PrPsc or a variant thereof
  • b) Transmissible Disease- Infectious entity is not a typical infectious disease process
201
Q

Prion diseases of humans (3)

A

A. Kuru - a spongiform encephalitis in man similar to scrapie in sheep

  • Kuru was found among Fore’ people in N. Guinea. The disease is marked by tremors, little or no dementia, incoordination, ataxia, somnolence, sleepiness
  • Kuru has been passed to animals
  • Kuru was transmitted by infected body parts of deceased to woman and children who consumed the remains of the dearly departed

B. Creutzfeld-Jakob Disease - presenile dementia - ataxia (loss of muscular coordination) myoclonic fasciculations, semiconsciousness, involuntary contraction of groups of muscle fibers

    • agent unknown - characteristic of unconventional agent - formalin treated brains produce infections after years -
    • pathology of disease is like Kuru
    • SAF found in infectious tissue
    • Transmitted by corneal transplants and contaminated brain electrodes
      • Possibly transmitted from sheep to human, mutton consumption in large quantities by members of certain populations points to this relationship, ie Lybian
      • Jews eat eye balls of sheep.

C. Other spongiform encephalopathies caused by mutated prions

    • Fatal Familial Insomnia (eventually die cause you can’t sleep)
    • Sporatic fatal insomnia
  • Alper’s, Pick’s, Alzheimer’s disease, possibly caused by unconventional agents
202
Q

Diseases caused by convential agents (viruses) - 2

A

A. Subacute Sclerosing Panencephalitis (SSPE)

  • Progressive demyelination, degenerative, neurological disease—–>fatal; enormous increase in hypertrophic astrocytes and proliferation of microglial cells
  • Causative agent of SSPE seems to be measles virus - helical nucleocapsid found in brain biopsy-
  • co-cultivation of biopsied cells with permissive cells grown in tissue culture induces measles virus-like formation
  • 1 case SSPE/million measles infection (high specific ab in blood and CSF)

B. Progressive Multifocal Leukoencephalopathy (PML)- Papovavirus (Small DNA virus)

  • PML associated with lymphoproliferative disorders - the disease is a progressive neurological disorder - disease is rare, virus is not, by 14 years 65% have Ab to JC virus – however, infection of immunocompromised – lead to paralysis, mental deterioration —-> death 1 year (lesions in both the gray and white matter infection of oligodendrocytes, non-inflammatory, normal
203
Q

Identify 2 onco viruses associated with Progressive Multifocal Leukoencephalopathy (PML)- Papovavirus (Small DNA virus)

A

CSF, hard to diagnose by serology, biopsy brain

  1. Two viruses associated with disease; both are papovaviruses
  • a. SV40 (primary infection possible upper respiratory infection or urinary infection)
  • b. JC virus

c. both oncogenic to lab animals

204
Q

A 10 day old infant is brought to the office because of fever, fussiness, and decreased appetite. Mom states the baby is inconsolable. Past medical history is unremarkable. Mother was Group B Strep positive but was treated with ampicillin prior to delivery.

On PE the baby is fussy, with a bulging fontanel.

**differential

A

Differential

Group B strep

  • Early onset; frist 7 days of life
  • Late onset; after 7 days of life

CNS infections

  • Meningitis
  • encephalities

Other infections

  • resp infection
  • UTI
205
Q
  1. A six year old is seen in the emergency department with fever and neck pain. He has had fever for the past four days. A classmate has recently been hospitalized.
    • On PE his temperature is 39. He appears ill and resists neck flexion.
  2. •A 12 year old boy is complaining of frontal headaches and fever for the past 3 days. He also has had some vomiting. He now has been having hallucinations and bizarre behavior.
A
  1. Meningitis
  2. more differential based on age
206
Q

CNS INFECTIONS

  • most common cause of what
  • Symptoms
  • Signs
A

Introduction

  • •Most common cause of fever associated with signs/symptoms of CNS disease
  • •Viral > bacterial > fungal > parasites
  • •Age specific pathogens

Symptoms; younger patients have unspecific findings

  • •Headache
  • •Nausea
  • •Vomiting
  • •Anorexia
  • •Restlessness
  • •Altered state of consciousness
  • •Irritability

Signs; younger patients have unspecific findings

  • •Fever
  • •Photophobia
  • •Bulging fontanel
  • •Neck pain
  • •Nuchal rigidity
  • •Obtundation
  • •Stupor
  • •Coma
  • •Seizures
  • •Focal neurologic deficits
207
Q

Types of CNS infection (2)

A

•Diffuse

  • –Meningitis: meninges primarily involved
  • –Encephalitis: parenchyma
  • –Meningoencephalitis: both

•Focal

  • –Brain abscess
208
Q

How do you diagnose diffuse CNS infections

A

Diagnosis of diffuse CNS infections depends on examination of CSF by *******LUMBAR PUNCTURE******

  • Meningitis
  • Encephalitis
  • Menngoencephalitis
209
Q

Causes of bacterial meningitis based on the following

  • Neonate (most common cause in neonae??)
  • 2 mo - 12 years
  • Immunosuppressed
A

•Neonate

  • –Group B Strep
  • –E. coli
  • –Listeria

•2 mos.-12 year

  • –Strep pneumo
  • –Neisseria meningitidis (military barracks and college students)
  • –H. flu b (used to be the most common type in this age group but vaccine has now helped it)

•Immunosuppressed

  • –Pseudomonas (cystic fibrosis)
  • –Staph (cystic fibrosis)
  • –Salmonella (sickle cell anemia)
  • –Listeria (also neonates and unpasteurized milk)
210
Q

Epidemiology of bacterial menigitis

6 risk factors

A
  • •Age
    • Younger children are immuno naive. Milder infections in older child can be more serious in younger children.
  • •Recent colonization
  • •Close contact (Neisseria, H. flu b)
  • •Black, Native American, Eskimo, male
  • •Splenic dysfunction
    • Sickle cell people usually have autosplenectomy (small or no spleen)
  • •Congenital/acquired CSF leak
    • Bar fight - punch and fracture cribiform plate
211
Q

Pathophysiology of bacterial meningitis

Pathogenesis

A

Pathophysiology

  • •Meningeal purulent exudate
  • •Ventriculitis
  • •Cerebral infarction
  • •Increased intracranial pressure
  • •Raised CSF protein-from ↑ permeability
  • •Hypoglycorrhachia-from ↓ glucose transport

Pathogenesis

  • •Bacteremia-posssibly from nasopharyngeal colonization
  • •Enter CSF through choroid plexus
  • •Multiply in CSF-low complement/Ab
  • •Inflammatory response triggered-can result in brain injury
212
Q

Clinical manifestations of bacterial meningitis

**Sudden vs insidious

A

•Sudden

  • –Shock
  • –Purpura
  • –Disseminated Intravascular Coagulopathy
  • –Can progress to coma, death w/in 24 h

•Insidious

  • –Fever for several days
  • –Associated with URI, GI
  • –Nonspecific signs-lethargy, irritability
213
Q

Tests to identify meningitis (4)

A

Meningeal irritation

  • •Nuchal rigidity
  • •Back pain
  • •Kernig
  • •Brudzinski
214
Q

Findings from spinal tap of patient with bacterial meningitis

  • WBC count
  • WBC type
  • Gram stain

Spinal tap - contraindications

  • what is not a contraindications
A

Spinal tap results

  • •Elevated white count
    • –Usually > 1000/mm3 (< 250 in 20%)
    • –Neonates may have 10-30 normally
    • –Children < 5
  • •Mostly neutrophils
  • •Positive Gram stain in 70-90% untreated

Spinal tap - contraindications

  • •Evidence of increased intracranial pressure
    • –3rd or 6th cranial nerve palsy (sign of increased ICP)
    • –Hypertension/bradycardia/respiratory (Cushing’s triad)
    • BULGING FONTANEL IS NOT A CONTRAINDICATION
  • •Severe cardiorespiratory compromise
  • •Skin infection over LP site
215
Q

Identify differential diagnosis of bacterial meningitis (4)

A
  • •Brain abscess
  • •Subdural empyema
  • •Noninfectious causes
    • –Malignancy
    • –Collagen vascular diseases
    • –Toxins
  • •Acute viral meningoencephalitis
216
Q

Treatment of bacterial meningitis based on age

**what is gold standard to tell you organism

  • neonate
  • strep pneumo
  • Neisseria
  • H flu b
  • Immunocompromised

Other non abx treatments

A

CULTURE is gold standard to tell you what organism. but you don’t really wait till results come out before starting treat. treat based on age.

NEVER DELAY THERAPY WAITING ON THE LP

Other non-abx

  • •Corticosteroids
    • –Limits production of inflammatory mediators
    • –Data supports use only in H. flu b meningitis
  • •Supportive
    • –IVF
    • –ICP
    • –Seizures
217
Q
  • Complications of bacterial meningitis (5)
  • Prognosis
  • Prevention
    • vaccinations for what 3 organisms
    • what abx prophylaxis
A

Complications of Meningitis

  • •Seizures
  • •Increased ICP
  • •Cranial nerve palsies
  • •Stroke
  • •Subdural effusions

Prognosis

  • •Mortality < 10% after neonatal period
  • •Pneumococcal meningitis has highest mortality
  • •10-20% have severe neurodevelopmental sequelae
  • •Prognosis worst for < 6 mo/o, high concentration bacteria in CSF
  • •Sensorineural hearing loss most common sequela

Prevention

  • •Vaccination
    • –H. flu b
    • –Strep pneumo
    • –Neisseria
  • •Antibiotic prophylaxis
    • –Neisseria-rifampin for close contacts (household, daycare, nursery school, healthcare exposed to oral secretions)
      • •Also ciprofloxacin, ceftriaxone
    • –H. flu b-rifampin (4h/day for 5/7 days)
      • •Also ceftriaxone, cefotaxime
218
Q

Viral meningoencephalitis

  • 3 types
  • which involves focal involvement (TEMPORAL LOBE INVOLVED)
A

Viral meningoencephalitis

  • •Enteroviruses most common
  • •Arboviruses
    • –Summer months
    • –Mosquitoes, ticks are vectors
    • –West Nile, St. Louis, California
  • •Herpes
    • –Focal involvement
    • –Death in 70% if not treated
219
Q

Identify CNS infections based on clinical manifestations

  • •Varies
  • •Usually acute onset after nonspecific febrile illness
  • •Headache-frontal, sometimes retrobulbar
  • •Fever, nausea, vomiting, photophobia
  • •Stupor, hallucinations, bizarre movements
  • •Seizures
  • •Paralysis
  • •Rashes
A

Viral Meningoencephalitis

For diagnosis; EEG, CT, MRI may be helpful

220
Q

Diagnosis of viral meningoencephalitis

Treatment (2)

A

Diagnosis

  • •Spinal tap
    • –Up to several thousand cells/mm3
    • –Mononuclears appear by about 8-24 h
    • –Nml to slightly elevated protein
    • –Glucose usually normal
    • –Culture, PCR
  • •Nasopharyngeal, rectal swabs for viral culture
  • •CSF serology is test of choice for West Nile Virus
  • •Acute and convalescent serology may be useful for arbovirus

Any findings suggestive of temporal lobe involvement should arouse suspicion of HSV

Treatment

  • Supportive
  • Acyclovir
221
Q

Prognosis of viral meningoencephalitis

A
  • •Most have complete recovery
  • •Mild to severe sequelae, especially with HSV
  • •Motor incoordination, seizures, deafness, visual disturbances, behavioral distrubances
  • •Poor prognosis if severe clinical illness and substantial parenchymal involvement
  • •Always do followup eye/ear
222
Q

Identify the following

  • •Choroid plexus
    • –Lateral 3rd/4th ventricles
  • •Filtration/active transport
  • •Adult volume
    • –125-150 ml
    • –20ml/h=500 ml/day
  • •20% in ventricles
  • •80% subarachnoid
  • •Arachnoid villi
    • –Superior sagittal, spinal n. roots
A

CSF - cerebrospinal fluid

223
Q
  • Indications for spinal tab for sample CSF (5)
  • Contraindications
  • complications
  • Procedure
  • Traumatic tap
A

Indications for spinal tap

  • •Suspected CNS infection
  • •Suspected subarachnoid hemorrhage
  • •Therapeutic reduction of CSF pressure
  • •Sampling of CSF for other reasons
  • •Delivering medications
    • E.g in ALL (acute lymphoblastic leukemia), you need to deliver chemo into the CNS? (intrathecal chemo)

Contraindications for spinal tap

  • •Local skin infection (absolute)
  • •Increased ICP (except pseudotumor)
  • •Suspected spinal cord mass/intracranial mass
  • •Uncontrolled bleeding diathesis
  • •Spinal column deformities (relative contraindication, may require fluoroscopic assistance)
  • •Hemodynamic instability
  • •Lack of patient cooperation

Complications

  • •Headache most common
  • •Epidermoid tumor-rare, manifests years later
  • •Infection
  • •Spinal hematoma
  • •Herniation-unlikely unless focal findings, coma

Procedure

  • Know your opening and closing pressure
  • Patient laying down or sitting up
    • Have patient bent so needle can go through
  • Level L3 (top of iliac crest trace to midline)

Traumatic tap

  • •1 WBC for every 500-1500 RBCs
  • WBCCSF=RBCCSF X (WBCperipheral/RBCperipheral
224
Q

CNS findings - pressure, WBC, protein, glucose, comments

  • normal
  • bacterial
  • partially tx (e.g tx w/ amoxillin)
  • viral
  • TB
  • fungal
  • brain abcess
A
225
Q

CV Disease and trauma (Cont’d) - NORTON

Identify Hypertensive CV disease (3)

A
  1. Lacunar Infarct (associated with HTN)
  2. Slit Hemorrhage
  3. Hypertensive Encephalopathy
226
Q

Describe lacunar infarcts (HTN CV disease)

***what does it cause?

A

Hypertension
a. Affects deep penetrating arteries and arterioles

  • 1) Basal ganglia
  • 2) Hemispheric white matter
  • 3) Brain stem

b. _Cause arteriolar sclerosis***_
c. Result: Single or multiple small cavity infarcts (lacunes)

  • 1) Tissue loss
  • 2) Scattered fat-laden macrophages
  • 3) Surrounding gliosis
  • 4) Occur in lenticular nucleus, thalamus, internal capsule, deep white matter, caudate nucleus, pons
  1. Clinical spectrum ranges from silent to severe neurologic impairment

_***Hypertensive CV disease likes to occur in BASAL GANGLIA_

227
Q

Describe Slit hemorrhages (Hypertensive CV disease)

3 points

A

Slit hemorrhages

  • Caused by hypertension
  • Small hemorrhages
  • Hemorrhages resorb causing a slit-like cavity surrounded by a brownish discoloration
228
Q

Describe hypertensive encephalopathy (Hypertensive CV disease)

A

Hypertensive Encephalopathy

1. Acute

  • a. Headache, confusion, vomiting, convulsions, sometimes coma
  • b. Rx: must be rapid in order to reduce intracranial pressure

2. Over months to years – resulting in multiple infarcts – results in:

a. Dementia, gait abnormalities, pseudobulbar signs, and often with superimposed neurologic deficits [syndrome called vascular (multi-infarct) dementia]
b. Multifocal vascular disease

  • 1) Cerebral atherosclerosis
  • 2) Vessel thrombosis or embolism
  • 3) Cerebral arteriolar sclerosis from chronic hypertension
  • 4) When predominantly white matter, called Binswanger disease
229
Q

Identify hemorrhage type and subtypes

    1. May occur at any site
    1. May occur at the site of infarct
    1. Trauma usually causes hemorrhage into epidural or subdural space (see above)
    1. Hemorrhage into brain parenchyma and and/or subarachnoid space is usually
  • due to underlying cerebrovascular disease
A

Intracranial Hemorrhage

  • Intracerebral (intraparenchymal) hemorrhage
  • Subarachnoid hemorrhage and ruptured berry aneurysms
  • Vascular Malformations
230
Q

Subtype of intracranial hemorrhage - Intracerebral (intraparenchymal) hemorrhage

  • define
  • morphology
  • clinical
A

1. Spontaneous (non-traumatic) rupture of a small intraparenchymal vessel

  • a. Occurs most frequently in mid to late adult life, peak age 60 years
  • b. Hypertension: causes more than 50%, htn results in
    • 1) Accelerated atherosclerosis (large vessel)
    • 2) Hyaline arteriolosclerosis (smaller vessel)
    • 3) In severe hypertension
      • a) Proliferative changes
      • b) Necrosis of arterioles
    • 4) Vessels are weaker, aneurysms form (Charcot-Bouchard microaneurysms) – most commonly in basal ganglia
    1. Morphology
  • a. Location when due to hypertension:
    • 1) Putamen (50-60%), thalamus, pons, cerebellar hemispheres (rarely)
      • a) Ganglionic hemorrhages
    • 2) Extravasation of blood causing compression of adjacent parenchyma
    • 3) If old there is a cavity
  • Clinical
    a. Location of bleed determines clinical manifestations: devastating, silent
    or evolving like an infarct
    b. Clinical improvement seen with resolution of hematoma
231
Q

Identify hemorrhage type

1) Occur in the lobes of the cerebral hemisphere
2) Most common cause is cerebral amyloid angiopathy (CAA)

  • a) Deposition of amyloidogenic peptides in walls of medium- and small-sized meningeal and cortical vessels which weakens the wall
  • b) Usually the same peptides as deposited in Alzheimer disease

3) Other causes: hemorrhagic diathesis, neoplasms, drug abuse,
infections, and noninfectious vasculitis

A

LOBAR HEMORRHAGES

232
Q

Subtype of Hypertensive CV disease - Subarachnoid hemorrhage and ruptured berry aneurysm

****What is the most common cause?

A
  1. Causes:
  • a. Rupture of a saccular (berry) aneurysm – most frequent cause
  • b. Extension of a traumatic hematoma
  • c. Rupture of a hypertensive intracerebral hemorrhage into the ventricular system
  • d. Vascular malformation
  • e. Hematologic disturbances
  • f. Tumors
  1. Berry aneurysm (saccular aneurysm, congenital aneurysm)
    a. Most common intracranial aneurysm
    [b. Other aneurysms: these do NOT usually give rise to subarachnoid hemorrhage
  • 1) Atherosclerotic (fusiform, usually of basilar artery)
  • 2) Mycotic
  • 3) Traumatic
  • 4) Dissecting]

c. 90% of Berry aneurysms occur in the ANTERIOR circulation at major
branch points, multiple aneurysms exist in 20-30% or cases

233
Q

Describe pathogenesis of subarachnoid hemorrhage

  • causes
  • predisposing factors
  • are they identifiable at birth>??
A

a. Etiology: unknown, majority are sporadic
* 1) Increases risk: Autosomal dominant polycystic kidney disease,

Ehlers-Danlos syndrome type IV, neurofibromatosis type I,
Marfan syndrome, fibromuscular dysplasia of extracranial
arteries, coarctation of the aorta
b. Predisposing factors: cigarette smoking, hypertension

c. NOT identifiable at birth

234
Q

subarachnoid hemorrhage

  • Morphology
  • Clinical
A

Morphology
a. Thin-walled outpouching

  • 1) Muscular vessel wall and internal elastic lamina are not in the wall of the aneurysm
  • 2) Wall of aneurysm has thickened, hyalinized intima; covered by adventitia that is continuous with parent artery

b. May see: atheromatous plaque, calcification or thrombotic occlusion
* *c. Usually ruptures at APEX of sac**

Clinical

  • a. Rupture is the most frequent complication (74% of patients have evidence of rupture)
  • b. Fifth decade, slightly more females
  • c. Sudden, excruciating headache
  • d. Rapid loss of consciousness
  • e. First rupture: 25-50% die
  • f. Rebleeding common in survivors
  • g. Acutely: vasospasm occurs
    • 1) Can occur in other vessels not originally injured
    • 2) Can cause addition ischemic injury
  • h. Late sequelae
    • 1) Meningeal fibrosis and scarring
    • 2) Obstruction to CSF flow and reabsorption
235
Q

Types of vascular malformations

A
  • AV malformations
  • Cavernous hemangioma
  • Capillary telangiectasia
  • Venous angioma (varies)
236
Q

Describe the 4 manifestions of vascular malformations

A
  1. Arteriovenous malformations
  • a. General
  • 1) Males 2X > females
  • 2) Most often detected between 10 and 30 years of age as a
    • a) Seizure disorder
    • b) Intracerebral hemorrhage
    • c) Subarachnoid hemorrhage
  • 3) Most common site: middle cerebral artery, esp. posterior branches
  • 4) If large and occurring in a newborn can cause CHF due to shunt effect esp. if occurring in vein of Galen (internal cerebral vein)
  • b. Morphology
  • 1) Occurs in
    • a) Subarachnoid going into brain OR
    • b) Within the brain
  • 2) Gross: tangled web, pulsatile
  • *2. Cavernous hemangioma**
    a. Greatly distended, loosely organized vascular channels
  • 1) Thin collagenized walls
  • 2) Devoid of intervening nervous tissue (differentiates this malformation from a capillary telangiectasia)

b. Most common locations: cerebellum, pons, and subcortical regions

  • *3. Capillary telangiectasia**
    a. Dilated, thin-walled vessels separated by relatively normal brain parenchyma
    b. Most commonly in pons

4. Venous angiomas (varices) – aggregates of ectatic venous channels

237
Q

Trauma

Describe skull fractures

  • definition
  • how it happens
  • fractures from one of which 5 bones
  • Symptoms
  • signs (2) - eyes and mastoid
  • meningeal tear results in?
  • High risk for?
A

A. Displaced fracture – bone is displaced into cranial cavity > thickness of bone
B. Occipital impact from fall while awake
C. Frontal impact from fall while unconscious
D. Basal skull fracture from impact to occiput or sides of head

    1. Fracture of at least one of five bones making up the base of the skull
      * a. Cribiform plate of ethmoid bone
      * b. Orbital plate of frontal bone
      * c. Temporal bone – petrous and squamous portions
      * d. Sphenoid bone
      * e. Occipital bone
    1. Symptoms: lower cranial nerve compromise
    1. Signs: Orbital hematoma (raccoon eyes) or mastoid hematoma (Battle’s sign)
    1. Meningeal tear resulting in CSF leak through the nose (CSF rhinorrhea) or ears (CSF otorrhea)
      * a. CSF has low protein and the presence of glucose
      * b. Mucus has high protein and NO glucose
      * c. Pathway for infection
    1. High risk for epidural hematoma from injury to middle meningeal artery
238
Q

Identfiy parenchymal injuries (3)

A
  1. Concussion
  2. Direct parenchymal injury
  3. Diffuse axonal injury
239
Q

Describe parenchymal injury - concussion

A

Concussion (closed injury)

  1. Altered consciousness following head injury
  2. Due to sudden change in momentum of head
  3. No acute gross nor histologic abnormalities
  4. Associated with
  • a. Temporary respiratory arrest
  • b. Loss of reflexes
  • c. Amnesia
    • 1) Retrograde – loss of memory of events shortly before trauma AND/OR
    • 2) Post-traumatic – loss of memory of events immediately after
  • d. Confusion
  • e. Headache – most common complaint
  • f. Other minor neurologic symptoms – impaired concentration, visual
  • disturbance, loss of balance, nausea, vomiting
  1. Postconcussive syndrome (recurrent headaches, impaired concentration, minor neurologic symptoms) – usually resolves within 7 days but may persist for
    several weeks to months
240
Q

Describe 3 forms of direct parenchyma injury

A

1. Cerebral contusion

a. Rupture of small vessels near the surface of the brain
b. Acceleration-deceleration injuries

  • 1) Coup – lesion corresponding to site of impact
  • 2) Contrecoup – lesion opposite site of impact (occurs if head is mobile at time of injury)

c. Morphology

  • 1) Early – pericapillary edema and hemorrhage
  • 2) Hours – bleeding throughout involved tissue, white matter and subarachnoid space
  • 3) 24 hours – evidence of neuronal injury (pyknosis of nucleus, eosinophilia of cytoplasm, disintegration of cell)
  • 4) Inflammatory response to injured tissue
  • 5) Old traumatic lesions – depressed, retracted, color changes to yellow-brown as heme is broken down (plaque jaune). May become site of epileptic focus

2. Cerebral laceration

a. Most severe type of injury
b. Tearing of cerebral tissue causing acute hemorrhage into

  • 1) Subarachnoid OR
  • 2) Subdural space

c. Profound neurologic dysfunction
d. HIGH mortality

  • *3. Penetrating (open) injuries**
    a. Due to gun shots and severe blunt trauma
    b. Cause severe brain damage with a high incidence of infection
    c. Symptoms and sequelae depend on
  • 1) Extent
  • 2) Area of damage
241
Q

Describe diffuse axonal injury

A
    1. Involves deep white matter regions
    1. Microscopic: Axonal swelling appearing hours after injury and focal hemorrhage. Later: increased microglia and degeneration of involved fiber tracts
    1. Cause: angular acceleration even without impact (up to 50% of pts who develop coma after trauma without cerebral contusions)
242
Q

Trauma - Traumatic Vascualr Injury (2)

A
  • Epidural Hematoma
    • Accumulation of blood between the skull and dura
    • Most often middle meningeal artery
    • Lucid period
  • Subdural Hematoma
243
Q

Describe traumatic vascular injury (epidural hematoma)

  • cause
  • signs and symptoms
  • what do they die of
A

Epidural Hematoma

    1. Accumulation of blood between the skull and dura (virtual space)
    1. Most common complication of NON-penetrating head injuries
      * a. 90% due to tear of a dural artery, most often middle meningeal artery (often associated with fracture of the temporal region of the skull)
      * b. 10% are venous in origin
    1. When arterial, expands rapidly – symptoms within hours
    1. When due to a venous bleed, symptoms develop more slowly
    1. Symptoms
      * a. Variable period of concussion (loss of consciousness) then
      * b. Conscious for up to several hours (lucid period) then
      * c. Headache, vomiting, altered consciousness, and papilledema
      * (ALL signs of increased intracranial pressure) then
      * d. Tentorial herniation rapidly follows
      • 1) Oculomotor nerve palsy (pupillary inequality first then failure to react to light
      • 2) Compression of brain stem (change of heart rate, blood pressure
      • and respiration)
      • 3) Untreated: coma and death
    1. Diagnose early since surgical evacuation early is successful
244
Q

Traumatic Vascular injury (Subdural hematoma)

  • 2 layers of dura mater
  • pathogenesis
  • morphology
  • clinical
A

1. Dura mater –

  • a. Two layers
    • 1) External collagenous layer
    • 2) Inner border cell layer with scant fibroblasts, and abundant extracellular space devoid of collagen
  • b. Bleeding separates layers
  • c. Accumulation of blood between the layers of the dura (NOT in the subdural space despite the name)

2. Pathogenesis

  • a. Trauma required is minimal – may have no history of trauma
  • b. Rupture of veins from cerebral cortex to the superior sagittal sinus (bridging veins)
    • 1) 10% are bilateral
    • 2) Bleeding is usually slow and self-limited
  • c. Common especially in elderly due to atrophy of the brain and stretching of the bridging veins

3. Morphology

  • a. Organization of the hematoma
    • 1) Lysis of clot (1 week)
    • 2) Growth of fibroblasts into hematoma (2 weeks)
    • 3) Early development of hyalinized connective tissue (1-3 months)
  • b. Hematoma is firmly attached to dura
  • c. Multiple episodes of rebleeding may occur (chronic subdural hematoma) from thin-walled vessels in granulation tissue

4. Clinical

  • a. Symptoms most often appear within first 48 hours
  • b. Intracranial pressure increases slowly causing symptoms:
    • 1) Headache, vomiting, papilledema
    • 2) Fluctuating consciousness
  • c. Also may develop
    • 1) Epileptic focus
    • 2) Neurologic symptoms (spastic paralysis is most common)
  • d. If prolonged, may cause atrophy and dementia
  • e. Treatment: surgical evacuation is curative – return of brain function is variable
245
Q

Sequelae of brain trauma

A

A. Chronic traumatic encephalopathy (CTE) –

    1. Develops after repeated head trauma such as concussions despite the belief that there are not structural sequelae of concussions
    1. Dementia
    1. Brain is atrophic with enlarged ventricles
    1. Neurofibrillary tangles in superficial frontal and temporal lobe cortex

B. Posttraumatic hydrocephalus – obstruction in subarachnoid space
C. Posttraumatic epilepsy
D. Increased risk of infection
E. Psychiatric disorders

246
Q

Spinal cord injuries

  • caused by
  • Basic injuries?
A

Spinal Cord injuries

A. Caused by:

    1. Forced movements (whiplash)
    1. Vertebral fractures
    1. Subluxations

B. Basic injuries

    1. Concussion, contusion, and laceration
    1. Often more severe due to concentration of neural pathways
    1. If high, then quadriplegia - death may occur if respiratory muscles are paralyzed
    1. Thoracic cord injury may lead to paraplegia and dysfunction of the bladder and rectum